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It is believed that the heterologous tolerance that develops upon chronic exposure to morphine is 
the result of adaptive changes in the cellular signaling pathways associated with the µ opioid 
receptor.  Proposed adaptive changes that occur in these signaling elements should occur as the 
changes in function appear in the whole animal and should spontaneously reverse as function 
returns to normal.  The length of time it takes for these adaptations to reverse should be 
proportional to the magnitude of tolerance that has developed.  To test these hypotheses, it is 
necessary to establish a complete time course for the development and decay of heterologous 
tolerance.  Such a time course has been documented in the LM/MP of the guinea pig following 
pellet implantation.  However, that method of administration only allows for a qualitative 
assessment of the nature of the decay of tolerance because the time at which morphine exposure 
ends is unknown.  We therefore, assessed the capacity of two different twice daily injection 
administrations (subcutaneous and intraperitoneal) to generate a time course for the development 
and decay of heterologous tolerance that was reproducible.  Animals were treated for 1, 2, 4, 7, 
or 10 days and then assessed for the appearance of tolerance via paw pressure testing in the 
whole animal and by measuring the response of the LM/MP to DAMGO and 2-CADO either 0, 
1, 2, or 4 days after the last treatment day.  Administration of morphine via intraperitoneal 
injection was found to produce tolerance that was highly variable, presumably due to variable 
absorption from the gut, making it unsuitable for the time course study.  Subcutaneous injection 
was shown to reproducibly induce tolerance in both the whole animal via paw pressure analgesic 
testing and in the response of the guinea pig LM/MP to DAMGO and 2-CADO.  The results of 
 
 
this study indicated that a significant level of tolerance begins to develop by 2 days of treatment 
which appears to become maximal and plateau by 4 days of treatment.  In addition, the tolerance 
observed after 2 days is not heterologous as evidenced by the lack of a significant change in the 
IC50 value for 2-CADO in the LM/MP.  By 4 days of treatment tolerance had become 
heterologous.  Despite the plateau after 4 days of treatment, LM/MP responses from animals 
treated for 7 or 10 days of treatment took longer (4 days) to return to baseline than animals 
treated for 4 days (2 days).  These data suggest that more extensive adaptations occur as 
treatment length increases despite the fact that the magnitude of change in the responses from the 
LM/MP and whole animal were not significantly different from each other after 4, 7, or 10 days 
of treatment.  Western blot analysis of LM/MP and brainstem homogenates from these same 
animals revealed that heterologous tolerance in these tissues is not the result of a decrease in the 
receptor number of either the µ, A1, A2a, or α2b receptors.  A trend was observed for the α3 
subunit isoform of the Na+/K+ ATPase in the LM/MP to decrease in abundance as tolerance 
develops and return to baseline as tolerance decays.  Although it was not statistically significant, 
the change in abundance is of a similar magnitude to significantly changed values previously 
reported in the literature.  A trend for an increase in the abundance of PKCε was also observed in 
the LM/MP.  This trend, though not significant, is in agreement with reported literature values in 
other tissues.  Contrary to the LM/MP results, PKCγ and PKCε showed a trend for a decrease in 
the brainstem while there was no change in the abundance of the α3 subunit of the Na
+/K+ 
ATPase there.  No change was observed in the brainstem for the α1 and β1 subunits of the Na
+/K+ 
ATPase as well.  The trends observed may indicate that the brainstem and the LM/MP develop 
tolerance by distinct mechanisms but more research will be necessary elucidate the role of the α3 
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 CHAPTER ONE: INTRODUCTION 
1.1 General Introduction 
Opium is the dried resin found in the seed pod of the opium poppy (papaver somniferum).  
The first undisputed reference to opium is found in the writings of Theophrastus but its 
therapeutic use likely predates recorded history.  It was historically used to treat a wide range of 
illness, including some for which it had no indication based on the medical knowledge of the 
time.  It was lauded by Sir Thomas Sydenham in 1680 that “Among the remedies which it has 
pleased almighty God to give to man to relieve his sufferings, none is so universal and so 
efficacious as opium.”  An entire class of drugs, opioids, has been developed based on alkaloids 
isolated from opium.  Opioids are among the most potent analgesic drugs known to man.  The 
term opioid refers to opiates, which are natural alkaloids present in opium, as well as synthetic 
substances derived from opiates and endogenous opioid peptides. 
Morphine (see figure 1.1) is the most abundant alkaloid found in opium.  It was first isolated 
from opium in 1804 by Friedrich Sertürner in what is believed to be the first isolation of a natural 
plant alkaloid in history.  Sertürner originally named the compound morphium after the Greek 
god of dreams, Morpheus, because it tended to cause drowsiness.  In 1817 Sertürner began 
distributing morphine and Merck began marketing the drug 10 years later in 1827.  After the 
hypodermic syringe came into use in 1857, the use of morphine became more widespread. 
Referred to as “God’s own medicine” by Sir William Osler (Osler, 1910), morphine was used in 
the civil war for its potent analgesic effect, during which time it was called “soldier’s joy (Yaksh 
& Wallace, 2011).” It has since become, and remains today, the gold standard for analgesic 
drugs.  Unfortunately, the use of “soldier’s joy” for chronic war wounds often  led to the 
“soldier’s disease (Yaksh & Wallace, 2011)” or opioid addiction.  Morphine’s beneficial effects 
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are subject to the development of tolerance and the drug possesses a number of toxic side effects 
as well as the potential to cause addiction leading Francis Peabody to revise Osler’s description 
of the drug based on his own experience with it saying that “depending upon how it is used it 
may be either ‘God’s Own Medicine’ or ‘The Devil’s Own Poison (Paul, 1999).’” 
The less favorable effects of morphine and other opiates prompted scientists to synthesize 
new compounds in search of one that had potent analgesic properties but lacked the side effects 
and abuse potential.  That search has yielded a number of new drugs (see table 1.1) that included 
agonists, antagonists, partial agonists, drugs with mixed agonist/antagonist properties, each 
having varying side effect profiles and efficacies.  While these new compounds have provided a 
wider range of therapeutic options, they also share many of the same liabilities that morphine 
has.  Opioids are also subject to the development of cross tolerance such that individuals tolerant 
to one opioid drug will likely display some degree of tolerance to other opioids as well.  
Research into the cellular mechanisms by which opioids act on biological systems and the 
mechanism(s) by which tolerance to their actions develops is still ongoing.  By understanding 
these mechanisms it may yet be possible to develop an opioid drug that is not subject to 
developing tolerance and does not cause addiction. 
1.2 The Endogenous Opioid System 
1.2.1 Opioid Receptors 
Although there was a vast amount of knowledge about the effects morphine and other opioids 
on living organisms, it wasn’t until the 1970s that any real understanding of how they function at 
a cellular level was ascertained.  Radioligand binding studies in the early 1970s revealed 
multiple binding sites for opiates on brain cell membranes (Goldstein, Lowney & Pal, 1971; Pert 
& Snyder, 1973).  In the mid to late 1970s the three classic opioid receptors (mu, kappa, and 
3 
 
delta) were characterized (Lord, Waterfield, Hughes & Kosterlitz, 1977; Martin, Eades, 
Thompson, Huppler & Gilbert, 1976).  Although the Greek letter nomenclature is still prevalent 
in the literature, in 2000 the Committee on Receptor Nomenclature and Drug Classification of 
the International Union of Pharmacology adopted and encourages the use of the terms MOP, 
DOP, and KOP (Mu Opioid Peptide receptor etc.) 
The sigma receptor was proposed as an opioid receptor and was discovered at the same time 
as the classic receptors. However, it was later shown that naloxone, an opioid antagonist, did not 
act as an antagonist at the sigma receptor (Manallack, Beart & Gundlach, 1986; Su, London & 
Jaffe, 1988).  More recently, cloning experiments have shown that the sigma receptor does not 
share the 7 transmembrane spanning domain structure typical of canonical G-protein coupled 
receptors that the mu, kappa, and delta receptors display (Hanner et al., 1996).  As a result of 
these findings, the sigma receptor is no longer considered to be an opioid receptor. 
In the 1990s a fourth receptor was recognized as an opioid receptor based on sequence 
homology to the other opioid receptors.  It was called either ORL1 (Mollereau et al., 1994) or 
LC132 (Bunzow et al., 1994) when it was initially cloned.  At the time it was an orphan receptor 
with no known endogenous ligand.  The endogenous ligand was later isolated and characterized 
by two groups independently who called it either orphanin FQ (Reinscheid et al., 1995) or 
nociceptin (Meunier et al., 1995).  Since the isolation of the endogenous ligand, the receptor has 
also been called the nociceptin/orphanin FQ receptor (N/OFQ) by some authors.  At the present 
time, the functions of the N/OFQ receptor are not well understood.  The receptor is expressed in 
a number of systems that endogenous opioids play a regulatory role in, thus it is hypothesized 
that it may play a similar regulatory type role. 
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A number of other opioid receptors have been proposed, but at the present time they are 
poorly characterized and their existence is not as widely accepted as the classic opioid receptors 
or the N/OFQ receptor.  These receptors include epsilon (Wüster, Schulz & Herz, 1979), iota 
(Oka, 1980), lambda (Grevel & Sadée, 1983), and zeta (Zagon, Goodman & McLaughlin, 1989).  
Additionally, it was suggested that via alternative splicing there may exist at least two receptor 
subtypes for each of the mu, kappa, and delta classes of receptors.  However, at the present time, 
cloning studies do not support the existence of these receptors as distinct classes.  It is believed 
that the modified specificity for opioid ligands could be accounted for by several underlying 
events as opposed to a difference in the receptor subtype (Yaksh & Wallace, 2011). 
Opioid receptors are found in the cell membrane where it is known that they can form both 
homo- and heterodimers.  Receptor heterodimers have different pharmacological properties than 
the specific type of receptors that compose them.  For example, mu-delta and delta-kappa dimers 
tend to have less affinity for highly selective agonists, show reduced agonist-induced receptor 
trafficking, and display a mutual synergy between receptor-selective agonists (Gupta, Décaillot 
& Devi, 2006).  Receptor dimerization is also thought to play a role in opioid tolerance.  
Opioid receptors are widely expressed both centrally and peripherally where they mediate 
several functions, including analgesia, behavioral responses such as reward reinforcement, and 
inhibition of respiration (see table 1.2).  Mu, kappa, and delta receptors are found in several 
regions of the brain and spinal cord linked to pain transmission and analgesia such as the 
periaqueductal gray, the rostral ventral medulla, and the dorsal horn of the spinal cord.  For a 
more detailed review of the anatomical distribution of opioid receptors and endogenous peptides 
see (Mansour, Khachaturian, Lewis, Akil & Watson, 1988; Sim & Childers, 1997). 
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1.2.2 Endogenous Opioid Ligands 
Around the same time as the characterization of the opioid receptors, their endogenous 
ligands were isolated.  Several classes of endogenous ligands exist.  The main three classes are 
endorphins, enkephalins, and dynorphins.  None are absolutely specific to a particular receptor, 
but the enkephalins appear to be somewhat selective for delta receptors, dynorphins are selective 
for kappa receptors, and endorphins are selective to mu receptors. In addition to these there are 
also the endomorphins, which are fairly mu selective, and N/OFQ, the ligand for the N/OFQ 
receptor.  The endogenous ligands are as widely distributed as the receptors and mediate a 
number of functions (see table 1.2).  All of these endogenous peptides are derived from larger 
precursor proteins.  Each of these precursor proteins is subject to digestion by trypsin-like 
enzymes resulting in a multitude of smaller peptides, some of which are active.  Most of the 
active peptides share a common sequence of amino acids, the opioid motif (Tyr-Gly-Gly-Phe-
(Met or Leu)) at the N-terminal end of the peptide (see table 1.3).  Notable exceptions to this are 
the endomorphins which have an atypical structure and N/OFQ which is lacking a hydroxyl 
group from the motif, which renders it inactive at mu, kappa, or delta receptors (Yaksh & 
Wallace, 2011). 
Endorphins are cleaved from prepro-opiomelanocortin (POMC).  POMC contains sequences 
for several non-opioid peptides as well.  Proteolytic cleavage of POMC yields 
adrenocorticotropic hormone (ACTH), β-lipotropin (β-LPH), and one of the melanocyte 
stimulating hormones (γ-MSH).  Further processing of β-LPH will produce γ-LPH and the opioid 
peptide β-endorphin. Although β-endorphin does contain the sequence for met-enkephalin, it is 
not converted this peptide.  POMC is mainly expressed in the arcuate nucleus of the 
hypothalamus and the nucleus tractus solitarius but it is also found in the anterior and 
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intermediate lobes of the pituitary and in pancreatic islet cells. Most of the circulating β-
endorphin is released from the pituitary with other pituitary hormones (Yaksh & Wallace, 2011). 
Enkephalins are derived from proenkephalin which contains several copies of met-
enkephalin and one copy of leu-enkephalin.  Proenkephalin peptides are expressed in areas of the 
central nervous system (CNS) that are thought to be related to the processing of pain 
information, to the modulation of affective behavior, motor control, and the autonomic nervous 
system, as well as neuroendocrinological functions.  Most of the circulating enkephalins are 
released from the chromaffin cells of the adrenal medulla and from nerve plexuses and exocrine 
glands of the stomach and intestines (Yaksh & Wallace, 2011). 
Dynorphins are derived from prodynorphin. This precursor protein contains the sequences for 
dynorphin A and B as well as the sequence for neoendorphin.  These peptides are distributed 
widely in neurons and are frequently co-expressed with other opioid peptides (Yaksh & Wallace, 
2011).  N/OFQ is widely distributed in the CNS though its physiological role is less understood 
than that of the endorphins, enkephalins, and dynorphins.  A more complete review of N/OFQ 
distribution and functions was published in 2013 (Donica, Awwad, Thakker & Standifer, 2013).  
Endomorphins, like the other opioid peptides, are widely distributed in the CNS and are thought 
to be involved in a multitude of processes (Fichna, Janecka, Costentin & Do Rego, 2007). 
A few other general points can be made regarding the endogenous opioid peptides.  Not all 
cells that make a given opioid precursor will release the same mixture of opioid peptides because 
of differences in the peptidases present in each cell.  A given cell may release a different mixture 
of opioid peptides depending on the current physiological demands the cell is experiencing.  And 
lastly opioid peptides can be released both centrally and peripherally.  The concentration of 
peptides in the plasma reflects release from peripheral systems and not release from neuraxial 
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systems.  The reverse is also true, the concentration of peptides in the cerebral spinal fluid are a 
reflection of release from neuraxial systems and are not associated with release from the 
periphery (Yaksh & Wallace, 2011). 
1.3 Basic Opioid Pharmacology 
1.3.1 Opioid Pharmacokinetics 
Opioids are fairly well absorbed but most are subject to extensive first-pass metabolism 
(Yaksh & Wallace, 2011).  As a result, when given orally, the therapeutically effective dose may 
be much higher than would be required if the drug were administered via some other route 
(subcutaneously, intramuscularly, etc.)  In addition, there is great variability in first-pass 
metabolism from person to person, making determining an effective oral dose difficult.  
Therefore, opioids are generally administered through other routes of administration including 
intravenous or subcutaneous injection, oral mucosa via lozenges, and transdermal patches. There 
are some opioids such as codeine and oxycodone that are more resistant to first-pass metabolism 
that are commonly administered orally (Yaksh & Wallace, 2011). 
Opioids bind to plasma proteins with varying affinity, but they tend to rapidly leave the blood 
and localize in high concentrations in highly perfused tissues such as the brain, lungs, liver, 
kidneys, and spleen (Schumacher, Basbaum & Way, 2012).  Despite the fact that the 
concentration of opioids that can be found in skeletal muscle is much lower than other tissues, 
skeletal muscle serves as the main reservoir due to the greater mass of skeletal muscle. Fatty 
tissue can also serve as a reservoir, especially after high-dose or chronic administration of 




Opioids are primarily metabolized by hepatic P450 enzymes to more polar compounds which 
are then excreted.  Most often, opioids undergo glucuronidation reactions.  Morphine has two 
glucuronide metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), 
both of which exert other effects (Yaksh & Wallace, 2011).  M3G has neuroexcitatory effects 
that do not appear to be mediated through the µ receptor and are currently undergoing further 
analysis (Schumacher, Basbaum & Way, 2012).  M6G does act through the µ receptor and has an 
analgesic potency 4-6 times that of its parent compound (Schumacher, Basbaum & Way, 2012).  
These metabolites are much more polar than the parent compound and therefore do not readily 
cross the blood brain barrier, so it is thought that they do not contribute much to the CNS effects 
observed after a single dose of morphine.  In addition to hepatic metabolism, some opioids such 
as heroin or remifentanil that contain esters are metabolized by plasma esterases (Schumacher, 
Basbaum & Way, 2012). 
The polar metabolites of opioids, as well as small amounts of the unchanged drugs, are 
primarily excreted in urine.  Glucuronide conjugates can also be found in bile but the 
enterohepatic circulation only accounts for a small portion of the excretory process (Schumacher, 
Basbaum & Way, 2012).  
1.3.2 Mechanism of Opioid Action 
All opioid receptors belong to the superfamily of G-protein coupled receptors.  This type of 
receptor is characterized by 7 transmembrane spanning domains coupled to a heterotrimeric G 
protein.  G proteins consist of an alpha and a beta/gamma subunit.  There are several types of 
alpha subunits, but opioid receptors are predominately coupled to pertussis toxin-sensitive Gi/Go 
alpha subunits.  All three of the major opioid receptors respond similarly when activated but 
since morphine and most of the other clinically relevant opioids act primarily at the mu receptor, 
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this section will focus on mu receptor activation. Upon acute receptor activation by an opioid, 
the GDP bound to the alpha subunit is replaced by GTP.  This causes a conformational change in 
the alpha subunit which destabilizes the heterotrimer causing it to dissociate into an alpha and a 
beta/gamma subunit, both of which have signaling consequences (see figure 1.2).  Being coupled 
to Gi/Go alpha subunits, one of the major consequences of opioid receptor activation is an 
inhibition of adenylyl cyclase, leading to a reduction in intracellular cyclic adenosine 
monophosphate (cAMP) levels. Gi/Go alpha also leads to an activation of protein kinase C (PKC) 
and phospholipase C-beta (PLCβ) as well as reducing the opening frequency of voltage-gated 
Ca2+ channels.  Additionally, the beta/gamma subunit enhances K+ efflux from the cell by 
opening G-protein coupled inwardly rectifying K+ channels (GIRKs).  There is also a Na+ 
component to opioid hyperpolarization that been suggested to be due to an increase in the 
function of the Na+/K+ ATPase (Masocha, González, Baeyens & Agil, 2002).  These signaling 
events are terminated via hydrolysis of the GTP to GDP on the alpha subunit allowing it to re-
associate with the beta/gamma subunit (Yaksh & Wallace, 2011). 
Mu receptors are present on both pre- and post-synaptic neurons and the activation at both 
sites results in an inhibition of signal transmission (see figure 1.3).  The closing of voltage-gated 
Ca2+ channels on pre-synaptic neurons prevents the release of neurotransmitters.  Post-synaptic 
neurons are hyperpolarized by the opening of GIRK channels and enhanced function of the 
Na+/K+ ATPase at the soma, thus dampening signal transmission, making it more difficult for 
these cells to generate action potentials (Schumacher, Basbaum & Way, 2012).  Given that 
opioid receptors are widely distributed and they operate on both pre- and post-synaptic neurons, 
it is not surprising that opioids produce such a potent analgesic effect.  Opioids act on the 
ascending pain transmission pathway starting at specialized nerve terminals in the periphery, 
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inhibiting the transmission of pain signals directly at the inflamed tissue (Schumacher, Basbaum 
& Way, 2012).  They also act in the dorsal horn of the spinal cord at what is sometimes referred 
to as the pain gate (see figure 1.4), dampening the transmission of pain signals to the brain.  
Opioids also enhance the activity of the descending inhibitory pathways which help to dampen 
pain signals at the spinal cord (Schumacher, Basbaum & Way, 2012). 
1.4 Clinical Application of Opioids 
Opioids are predominately used for their potent analgesic effect to treat severe or chronic 
pain but there are a few other indications for them as well.  Morphine has been used clinically in 
patients with acute pulmonary edema associated with left ventricular heart failure to relieve 
dyspnea.  Several mechanisms have been proposed as to how morphine produces this effect.  
These mechanisms include reducing anxiety, which is thought to reduce the perception of 
shortness of breath, and by reducing cardiac preload and afterload.  Morphine is also useful in 
treating painful myocardial ischemia associated with pulmonary edema.  Dextromethorphan and 
codeine are useful as antitussives at doses lower than those required for analgesia.  The 
mechanism of antitussive action is not clearly understood at the present time but it is thought that 
both central and peripheral effects have a role.  Diarrhea from almost any cause can be controlled 
with opioids, most commonly diphenoxylate or loperamide employed due to their more selective 
GI effects with little to no CNS effects.  However, if the underlying cause of diarrhea is an 
infection, opioids are not to be considered a substitute for the appropriate chemotherapeutic 
agents.  Opioids, meperidine in particular, are also reported to reduce shivering.  This particular 
response appears to be mediated through effects on α2 adrenoceptor subtypes as opposed to 
effects generated from one of the opioid receptors (Schumacher, Basbaum & Way, 2012).  
Opioids are also frequently used as premedicant drugs before anesthesia for their sedative, 
11 
 
anxiolytic, and analgesic properties.  They are also used as adjuncts to anesthetic agents or in 
higher doses as a primary component of an anesthetic regimen.  Opioids are commonly used with 
anesthetics in cardiovascular surgeries and other types of high risk surgeries where minimizing 
cardiovascular depression is a priority (Schumacher, Basbaum & Way, 2012). 
1.5 Adverse Effects of Opioids 
Given that opioid receptors are widely distributed, it should not be surprising that in addition 
to the clinical benefits that opioids provide, they are also responsible for a number of adverse 
effects.  One of the largest concerns with acute opioid administration is marked respiratory 
depression, which becomes more severe as the dose increases.  At high enough doses this effect 
can be fatal.  Although opioid actions in the GI system can relieve diarrhea in people suffering 
from this condition, opioids will cause constipation in patients who have normal GI function.  
This effect is also more severe with greater doses.  Opioids can activate the chemoreceptor 
trigger zone in the brainstem resulting in nausea and vomiting.  Endogenous opioid peptides also 
play a role in the homeostatic regulation of body temperature and thus administration of centrally 
active opioids may result in alterations of body temperature.  Morphine can act in the anterior 
hypothalamus at µ receptors to produce hyperthermia while other opioids acting at κ receptors 
can produce hypothermia.  Most of the beneficial and adverse effects of opioids are subject to the 
development of tolerance.  However, the miosis that occurs with virtually all opioid agonists 
seems to develop little to no tolerance.  Constriction of the pupils can be seen in even the most 
tolerant addicts. 
Prolonged use of opioids may lead to the development of tolerance, physical 
dependence/withdrawal, and psychological dependence/addiction.  Tolerance is defined as the 
loss of responsiveness to an agent that occurs as a result of repeated exposure to that agent.  
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Tolerance to the analgesic effect can be overcome by increasing the dose of the drug.  The 
problem with this solution is that not all of the side effects will develop tolerance at the same rate 
as the analgesic effect and some effects do not develop an appreciable level of tolerance at all.  
As a result, higher doses will result in greater toxicity.  Opioid tolerance is an extremely complex 
phenomenon.  The degree of tolerance that develops and how long that tolerance persists after 
withdrawal of the drug depends on the effect, which opioid is used, and a number of genetic and 
epigenetic factors.  Tolerance develops to the agonistic effects of opioids, but not to antagonists 
or to the antagonistic properties of mixed agents.  There is also a degree of cross tolerance that 
occurs with opioids, particularly with opioids that are primarily µ selective, but this tolerance is 
often partial or incomplete.  This incomplete tolerance among opioids is the basis behind the 
“opioid rotation” strategy that is used clinically to overcome tolerance.  Despite years of research 
the cellular mechanism(s) underlying the development of tolerance are still not fully understood.  
This topic will be discussed in detail in section 1.6. 
Physical dependence on an opioid is defined as requiring an opioid drug in order to maintain 
normal physiological function.  This should not be confused with psychological 
dependence/addiction as it is possible for someone to be physically dependent on an opioid but 
not addicted to it.  Physical dependence almost invariably occurs as a patient develops tolerance 
to the opioids that act primarily on the µ receptor.  The withdrawal syndrome that occurs is a 
result of an exaggerated rebound from the acute effects of the opioid.  Symptoms of withdrawal 
can include rhinorrhea, lacrimation, yawning, chills, gooseflesh (piloerection), hyperventilation, 
hyperthermia, mydriasis, muscular aches, vomiting, diarrhea, anxiety, and hostility.  Which of 
these symptoms manifest, and the intensity of the symptoms, will be dependent on the extent to 
which physical dependence has developed.  Giving an opioid agonist to a patient suffering from 
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opioid withdrawal will quickly ameliorate any symptoms.  Similarly, giving an opioid antagonist 
such as naloxone to someone who has developed physical dependence, but who has not stopped 
taking an opioid, will precipitate withdrawal symptoms.  The time of onset, intensity, and 
duration of withdrawal symptoms depend on the opioid used as well as the setting in which it is 
used and appears to be associated with the half-life of the drug.  For example, the withdrawal 
symptoms associated with chronic methadone exposure take longer to peak and are less severe 
than those seen with morphine or heroin.  This fact was the basis for using methadone in clinics 
to aid in the detoxification of heroin addicts.  However, even once the physical dependence has 
subsided; there still remains the possibility of psychological dependence or addiction. 
Addiction is defined by the American Society of Addiction Medicine as a primary, chronic 
disease of brain reward, motivation, memory, and related circuitry.  Dysfunction of these circuits 
leads the affected person to pathologically seek reward and relief through substance abuse.  
Psychological dependence/addiction is characterized by the inability to consistently abstain from 
using a drug, impairments in behavioral control, drug craving, diminished ability to recognize 
significant problems with one’s behaviors and interpersonal relationships, and a dysfunctional 
emotional response.  Opioids are associated with high risk of developing addiction, but despite 
this risk, opioids are not to be withheld if there are no other options to adequately control a 
patient’s pain (Schumacher, Basbaum & Way, 2012).  
1.6 Cellular Mechanisms of Opioid Tolerance 
As stated previously, the development of tolerance to the analgesic effect of opioids that 
occurs when they are used for prolonged periods of time is a serious obstacle to the successful 
management of chronic pain, such as pain associated with cancer.  Despite many years of 
research, the mechanisms that underlie the development of tolerance have still not been fully 
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elucidated.  It is believed that tolerance is the result of cellular adaptations that occur as part of a 
homeostatic response to the constant presence of opioid agonists in the body (Collier, 1966; 
Johnson & Fleming, 1989; Koob & Bloom, 1988).  There are five criteria that have been 
proposed that must be met in order for a potential cellular mechanism to be identified as 
accounting for the observed change in responsiveness (i.e. tolerance): “The proposed cellular 
change must: 1) be induced by experimental procedures identical to those that induce tolerance 
and/or dependence; 2) follow a similar time course as the tolerance and/or dependence in that 
tissue; 3) quantitatively account for the tolerance and/or dependence; 4) account for the 
qualitative characteristics of the tolerance and/or dependence; and 5) occur in the very cells upon 
which the opioid is acting (Taylor & Fleming, 2001)”.  Opioid tolerance is a complex 
phenomenon in part because several forms of tolerance are known to exist.  These different 
forms of tolerance can occur independently or simultaneously depending on the method used to 
induce tolerance. 
Homologous tolerance is a form of reduced responsiveness that is confined to a single 
receptor system, in this case the µ receptor system.  It typically occurs over a short period of time 
(seconds to hours) after exposure to high concentrations of agonist.  One example of this form of 
tolerance is the receptor desensitization that occurs within seconds upon acute exposure to high 
concentrations of agonist (Johnson & Fleming, 1989; Law & Loh, 1999).  Another form of 
homologous tolerance that has been proposed appears to be due to changes in the adenylyl 
cyclase cascade and develops more slowly over a few hours after agonist exposure (Nestler & 
Aghajanian, 1997; Nestler, Alreja & Aghajanian, 1994).  In contrast, heterologous tolerance is a 
form of tolerance that extends beyond the single receptor system that the agonist responsible for 
its development acts on.  This form of tolerance can take days to develop and decay.  An 
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example of this form of tolerance has been proposed to be due to a partial depolarization of the 
cell membrane potential that can be accounted for by a down-regulation of the sodium pump and 
a corresponding decrease in its electrogenic contribution to the membrane potential (Fleming, 
1999; Fleming & Taylor, 1995).  This section will describe several of the mechanisms proposed 
by various laboratories. 
1.6.1 Receptor Desensitization and β-arrestin mediated Internalization 
Receptor desensitization is a fairly common mechanism by which signaling from many G-
protein coupled receptors can be terminated acutely.  Desensitization can be distinguished from 
longer lasting cellular tolerance by its quick reversal upon removal of the opioid agonist that 
induced the desensitization.  Some of the first works that examined this phenomenon in the 
opioid receptor system were conducted in the early 1980s by Gahwiler and Law (Gähwiler, 
1981; Law, Hom & Loh, 1982). A general mechanism for desensitization of G-protein coupled 
receptors has been described by Lefkowitz that is consistent with what has been observed with 
the µ receptor (Pierce, Premont & Lefkowitz, 2002).  Briefly, this mechanism consists of the 
agonist binding the receptor, after which the receptor is phosphorylated allowing β-arrestin to 
bind to the receptor causing G protein uncoupling, desensitization, and/or internalization.  If the 
receptor is internalized, it is either marked for degradation or it is recycled back to the membrane 
where it can become reactivated.  A relatively new concept that has been developed from 
pharmacological studies of G-protein coupled receptors is that of biased agonism or functional 
selectivity (Kenakin, 2011).  Functional selectivity is the observation that different ligands for a 
given receptor stabilize slightly different conformations of the receptor such that certain 
signaling pathways may be favored depending on which agonist is used.  Functional selectivity 
has been observed in opioid receptor pharmacology in the context of desensitization at the steps 
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of receptor phosphorylation, endocytosis, and trafficking after endocytosis (Kelly, 2013; 
Pradhan, Smith, Kieffer & Evans, 2012; Raehal, Schmid, Groer & Bohn, 2011).  This concept 
may also help explain the partial tolerance between opioids that is the basis for the opioid 
rotation strategy used in chronic pain patients.  It may also help explain why very little 
internalization occurs upon acute morphine exposure when compared to acute DAMGO 
exposure as well (Patierno, Anselmi, Jaramillo, Scott, Garcia & Sternini, 2011).  
Phosphorylation of the µ receptor is known to occur at numerous sites and is mediated by a 
number of different proteins (see figure 1.5).  Fitting with the concept of biased 
agonism/functional selectivity, Lau et al. were able to characterize two such regions on the C 
terminal tail of the µ receptor that are quantitatively differentially phosphorylated by the µ 
selective peptide DAMGO and morphine (Lau et al., 2011).  As seen in figure 1.5, there is 
evidence to support the involvement of a number of different protein kinases in µ receptor 
phosphorylation.  G protein coupled receptor kinases (GRKs) 2, 3, and 5 appear to mediate 
phosphorylation upon exposure to morphine and DAMGO (Doll, Pöll, Peuker, Loktev, Glück & 
Schulz, 2012).  In addition, PKC isoforms α, βII, γ, and ε have been shown to phosphorylate the 
µ receptor (Doll, Konietzko, Pöll, Koch, Höllt & Schulz, 2011; Feng, Li & Wang, 2011).  
Phosphorylation of the µ receptor by GRK appears to be a prerequisite to the binding of β-
arrestin (Johnson et al., 2006; Whistler & von Zastrow, 1998).  Both β-arrestin 1 and 2 (also 
called arrestin 2 and 3) have been implicated in the desensitization and internalization of µ 
receptor (Johnson et al., 2006) although β-arrestin 2 may be more involved with morphine 
mediated desensitization (Bohn, Dykstra, Lefkowitz, Caron & Barak, 2004).  The µ receptor can 
also be desensitized via another mechanism independent of β-arrestin that does not result in 
receptor internalization and appears to be mediated by PKC phosphorylation (see figure 1.6) 
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(Allouche, Noble & Marie, 2014; Johnson et al., 2006).  Once the µ receptor has been 
internalized it can be sequestered into endosomes, recycled back to the cell surface and 
reactivated, or targeted for degradation.  Unlike other types of GPCRs, trafficking of the µ 
receptor for recycling or lysosomal degradation does not depend completely on ubiquitination 
(Hislop, Henry & von Zastrow, 2011).  The recycling of the receptor to the membrane surface 
was enhanced upon treatment with the non-selective kinase inhibitor staurosporine, indicating 
that some of the kinases sensitive to staurosporine inhibition are involved with µ receptor 
recycling (Arttamangkul, Lau, Lu & Williams, 2012).  Resensitization of µ receptor after 
morphine induced desensitization appears to involve dephosphorylation-mediated by protein 
phosphatases sensitive to calyculin A but not okadaic acid (Levitt & Williams, 2012). 
1.6.2 Receptor Down-regulation 
Receptor down-regulation is another common mechanism by which GPCR signaling is 
reduced in response to exposure to high concentrations of agonists.  β adrenergic receptors, for 
example, are known to be down-regulated when chronically exposed to short acting β 
adrenoceptor agonists, which limits their use clinically to short term applications.  There are 
conflicting reports about whether chronic treatment with opioids may or may not lead to changes 
in receptor abundance. Some labs report that chronic morphine treatment down-regulates the µ 
receptor (Bernstein & Welch, 1998; Yoburn, Billings & Duttaroy, 1993) while others report no 
change in receptor abundance (De Vries, Tjon Tien Ril, Van der Laan, Mulder & Schoffelmeer, 
1993; Klee & Streaty, 1974).  In contrast, there are a few reports suggesting that up-regulation of 
the receptors occurs with chronic treatment (Fábián, Bozó, Szikszay, Horváth, Coscia & Szücs, 
2002; Rothman et al., 1991).  Although there are instances where receptor down-regulation and 
cellular tolerance have been observed concomitantly, it is generally accepted that receptor down-
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regulation is not required for the development of cellular tolerance (Gomes, Shen, Stafford, Patel 
& Yoburn, 2002).  In addition, it appears the opioid used to induce tolerance has an important 
impact on whether or not receptor down-regulation occurs.  For example, it has been shown that 
chronic treatment with morphine results in little to no down-regulation while chronic treatment 
with etorphine or other high-intrinsic-efficacy agonists does (Stafford, Gomes, Shen & Yoburn, 
2001; Yabaluri & Medzihradsky, 1997).  While receptor down-regulation is not required for the 
development of tolerance, the Yoburn group has suggested that down-regulation does contribute 
to the magnitude of tolerance that develops to those opioid agonists that have been shown to 
cause down-regulation (i.e. etorphine) (Gomes, Shen, Stafford, Patel & Yoburn, 2002; Shen, 
Benedict Gomes, Gallagher, Stafford & Yoburn, 2000; Stafford, Gomes, Shen & Yoburn, 2001).  
As morphine is not an agonist that tends to cause µ receptor down-regulation, it follows that 
down-regulation likely does not play a significant role in the cellular tolerance that develops as a 
result of chronic morphine treatment. 
1.6.3 Adenylyl Cyclase, cAMP, and G-Protein Coupling 
As discussed in section 1.3.2, activation of µ receptors results in hyperpolarization of 
neurons by opening GIRK channels.  However, the opening of GIRK channels cannot 
completely explain the hyperpolarization that occurs.  Opioid exposure has also been shown to 
suppress a resting Na+ dependent inward current (Alreja & Aghajanian, 1993).  One of the other 
signaling events that occurs after acute µ receptor activation is an inhibition of adenylyl cyclase 
(see figure 1.2), reducing the level of cAMP that is produced and thus reducing signaling within 
this cascade.  The decrease in signaling of the adenylyl cyclase cascade has been suggested by 
the Nestler group to be responsible for the Na+ dependent component of opioid action (Nestler, 
Alreja & Aghajanian, 1994).  They have been able to show that chronic opioid exposure leads to 
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an up-regulation of the adenylyl cyclase cascade in several brain regions thought to mediate the 
opioid analgesic response (Nestler & Aghajanian, 1997; Nestler, Alreja & Aghajanian, 1994).  A 
homeostatic increase in the activity of adenylyl cyclase to counter the constant inhibition caused 
by chronic opioid presence, such as the Nestler group has suggested, is consistent with the 
hypothesis that tolerance to chronic morphine exposure is mediated by adaptive changes in a 
number of proteins.  Indeed, they have been able to show that chronic morphine treatment 
increases the abundance of adenylyl cyclase I and VIII isoforms in the rat locus coeruleus 
(Nestler & Aghajanian, 1997).  Similar changes in the adenylyl cyclase cascade have been 
reported in the guinea pig LM/MP as well (Chakrabarti, Wang, Tang & Gintzler, 1998).  In 
addition to an increase in adenylyl cyclase isoforms, the Nestler group has also been able to 
demonstrate increases in the Gi/o and Gs alpha subunits in the rat locus coeruleus in response to 
chronic morphine treatment (Nestler, Alreja & Aghajanian, 1994; Nestler, Erdos, Terwilliger, 
Duman & Tallman, 1989). 
Also of note is that the changes in the adenylyl cyclase cascade in the LM/MP have been 
reported by the Gintzler group to be due to a shift in G-protein coupling from a Gi/o alpha subunit 
to a Gs alpha subunit (Chakrabarti, Chang & Gintzler, 2010; Chakrabarti, Regec & Gintzler, 
2005; Chakrabarti, Wang, Tang & Gintzler, 1998).  In addition to this, work from the Gintzler 
laboratory has suggested that the adaptations responsible for the development of tolerance are 
not simply a hard-wired response to prolonged exposure to opioids (Gintzler & Chakrabarti, 
2008; Shy, Chakrabarti & Gintzler, 2008).  In fact, the nature of the adaptations that occur 
depend on the state of the cell and whether or not the consequence of µ receptor activation is 
inhibition or stimulation of adenylyl cyclase.  Experiments conducted by this group in which the 
investigators overexpressed adenylyl cyclase II along with a constitutively active Gs alpha 
20 
 
subunit created an environment in which the activation of the µ receptor resulted in an increase 
instead of a decrease in cAMP.  The increase in adenylyl cyclase and shift to Gs alpha signaling 
that occurs in a cellular environment that is inhibitory as far as adenylyl cyclase is concerned 
does not occur in the stimulatory environment. 
While it is clear that changes occur in the adenylyl cyclase system during the development of 
opioid tolerance, it is unclear what this change contributes to the development of tolerance in the 
LM/MP.  It has been shown that cAMP has no direct impact on the electrical properties of 
neurons in the LM/MP in untreated animals (Johnson & Pillai, 1990).  Although cAMP does not 
directly impact the electrical properties in untreated neurons, over time alterations in signaling 
within this cascade could possibly change the expression of proteins that play a role in the 
establishment/maintenance of membrane potential, such as the Na+/K+ ATPase. 
1.6.4 Protein Kinase C 
As mentioned in section 1.6.1, a number of protein kinases are thought to play a role in 
receptor desensitization and internalization by directly phosphorylating the mu receptor.  Protein 
kinase C has generated some interest in the context of the long lasting cellular tolerance to 
opioids.  It is known that chronic administration of opioids leads to an increase in PKC activation 
(Granados-Soto, Kalcheva, Hua, Newton & Yaksh, 2000) and translocation of PKC to the 
membrane (Kramer & Simon, 1999).  Additionally, inhibiting PKC before long-term morphine 
treatment prevents the development of analgesic tolerance (Gabra, Bailey, Kelly, Smith, 
Henderson & Dewey, 2008).  Administration of either non-specific or subtype specific inhibitors 
of the α, γ, and ε isoforms of PKC reverses antinociceptive tolerance after it has developed 
(Javed, Dewey, Smith & Smith, 2004; Smith, Gabra, Smith, Redwood & Dewey, 2007).  
Because PKCγ is only expressed centrally (Aley & Levine, 1997; Wang & Wang, 2006), it was 
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suggested that the α and ε isoforms mediate peripheral nociception while PKCγ mediates central 
nociception (Velázquez, Mohammad & Sweitzer, 2007). 
Work done by the Rodríguez-Muñoz group suggested a mechanism by which opioids can 
disinhibit signals from the periaqueductal gray, a part of the descending inhibitory pathway, and 
how acute tolerance can arise from this brain region.  They suggested that in this brain region the 
µ receptor is coupled to the NR1 subunit of the NMDA receptor (Rodríguez-Muñoz, Sánchez-
Blázquez, Vicente-Sánchez, Berrocoso & Garzón, 2012).  They further suggest that under 
normal conditions this association is of little consequence, but after stimulation by morphine, a 
negative feedback loop is triggered whereby NMDA receptors reduce the signaling capacity of µ 
receptors (Rodríguez-Muñoz, Sánchez-Blázquez, Vicente-Sánchez, Berrocoso & Garzón, 2012). 
Activation of µ receptors by morphine initiates a signaling cascade where the βγ subunit of the 
receptor acts through PI3K-Akt-nNOS to produce nitric oxide (Sánchez-Blázquez, Rodríguez-
Muñoz & Garzón, 2010).  Nitric oxide releases zinc ions from endogenous stores that recruit 
PKCγ and Raf-1 to the HINT1 protein at the µ receptor C-terminus (Rodríguez-Muñoz, de la 
Torre-Madrid, Sánchez-Blázquez & Garzón, 2011; Rodríguez-Muñoz, de la Torre-Madrid, 
Sánchez-Blázquez, Wang & Garzón, 2008).  PKCγ is then proposed to separate the µ receptor 
and NMDA receptor complex and activate Src, producing enhanced Ca2+ influx by NMDA 
receptors (Sánchez-Blázquez, Rodríguez-Muñoz, de la Torre-Madrid & Garzón, 2009).  This 
enhanced Ca2+ influx opposes the effect of µ receptor activation, thus reducing the efficacy of 
morphine at the periaqueductal gray.  This group has also shown that PKA, but not PKC, 
inhibition reduces the NMDA-induced antagonism of the analgesic effects of morphine 
(Rodríguez-Muñoz, Sánchez-Blázquez, Vicente-Sánchez, Berrocoso & Garzón, 2012).  This 
mechanism could potentially explain the observation by Zeitz and colleagues that PKCγ null 
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mice develop tolerance to the analgesic effects of morphine and clonidine to a lesser degree than 
wild-type littermates (Zeitz, Malmberg, Gilbert & Basbaum, 2001). 
Interestingly, Lin and colleagues recently took a different approach and demonstrated that 
increasing PKCα or PKCε activity at the pre-Bötzinger complex increases the level of tolerance 
to the respiratory depression that occurs as a result of opioid exposure (Lin, Law & Loh, 2012).  
The depressive effect opioids have on respiration does not develop tolerance as quickly or to the 
same extent to which the analgesic effect does, which causes it to be a significant problem when 
higher doses are used to overcome analgesic tolerance.  Given the extensive body of work that 
exists, PKC may play an integral part in the development of tolerance to morphine. 
1.6.5 µ-δ Heterodimerization 
 Over the past decade it was demonstrated that GPCRs can form homomers or heteromers 
and that doing so has an effect on the ligand binding, signaling, and trafficking properties of the 
receptors (Smith & Milligan, 2010).  It was shown in the early 2000s that opioid receptors can 
form heterodimers, particularly κ-δ and µ-δ dimers (George et al., 2000; Gomes, Jordan, Gupta, 
Trapaidze, Nagy & Devi, 2000; Jordan & Devi, 1999).  Since this time µ-δ heteromerization has 
been studied extensively.  The dimerization of these two receptors plays a role in some of the 
adverse effects associated with opioids, including the development of tolerance (Gupta et al., 
2010; He et al., 2011).  Mice lacking the δ receptor do not develop tolerance to morphine (Zhu et 
al., 1999).  Following chronic morphine treatment, it was observed that there is an increased 
abundance of µ-δ heteromers (Gupta et al., 2010).  The µ-δ heteromers activate β-arrestin 2 
mediated signaling which targets the heteromer for degradation (Rozenfeld & Devi, 2007).  
Disruption of heteromer appears to increase the analgesic effect of morphine by preventing the 
co-degradation of the heteromer (He et al., 2011).  There is also evidence to suggest that µ-δ 
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heteromers are associated with Gzα subunits as opposed to the Giα subunit usually associated 
with either receptor independently (George et al., 2000). 
The µ-δ heteromers respond to drugs differently than homomers of either of these receptors.  
Signaling assays with classical µ agonists such as morphine, DAMGO, fentanyl, and methadone 
in cells expressing the µ-δ heteromer or homomers of each receptor revealed that the potency of 
these drugs was approximately 7-12 fold greater in cells expressing the µ-δ heteromer than in 
cells expressing µ receptor homomers and no activity in cells expressing the δ receptor homomer 
(Yekkirala, Banks, Lunzer, Negus, Rice & Portoghese, 2012; Yekkirala, Kalyuzhny & 
Portoghese, 2010).  The same authors also found that the δ selective antagonist naltrindole 
antagonized the signaling mediated by morphine, fentanyl, and methadone only in cells that 
expressed the µ-δ heteromer and it antagonized the antinociceptive effect of these drugs in 
monkeys (Yekkirala, Banks, Lunzer, Negus, Rice & Portoghese, 2012).  These findings led the 
Portoghese group to suggest that the µ-δ heteromers are the primary target for the antinociceptive 
effects of morphine, fentanyl, and methadone as well as for the development of analgesic 
tolerance.  Inhibitors of δ receptors of µ-δ heteromers enhances the cellular response of the µ 
receptor, resulting in a greater antinociceptive effect upon activation by morphine (Gomes, 
Gupta, Filipovska, Szeto, Pintar & Devi, 2004).  These results have prompted efforts to 
synthesize drugs that can target the µ-δ heteromers.  These efforts led to generation of the 
bivalent ligand MDAN21, a compound comprised of the δ selective antagonist DN20 separated 
by a 21 atom spacer from the µ selective agonist MA19 (Daniels, Lenard, Etienne, Law, Roerig 
& Portoghese, 2005).  MDAN21 has a potency 100 times greater than morphine and develops 
little tolerance or dependence (Daniels, Lenard, Etienne, Law, Roerig & Portoghese, 2005).  
Other compounds have also been generated, but their properties have yet to be adequately 
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assessed and at the present time there are no bivalent ligands in clinical trials (Fujita, Gomes & 
Devi, 2015). 
1.6.6 Na+/K+ ATPase α3 subunit 
The Na+/K+ ATPase has been of interest in the context of morphine tolerance since the 
1970s.  Goldstein and his group used the LM/MP preparation to demonstrate morphine tolerance 
in the ileum of guinea pigs and observed that the LM/MP from tolerant animals were 
subsensitive to the inhibitory effects of morphine and supersensitive to the stimulatory effects of 
5-hydroxytryptamine (Schulz & Goldstein, 1973).  However, the magnitude of the 
hyperpolarization produced by receptor activation was similar in neurons from either placebo 
treated or morphine treated animals (Meng, Malanga, Kong, Taylor & Fleming, 1997). Based 
upon work done in the guinea pig vas deferens, Fleming and his group proposed that the results 
obtained by Goldstein et al. could be explained by an adaptive partial depolarization of the 
myenteric neurons similar to the depolarization observed in supersensitive smooth muscle cells 
of the vas deferens (Fleming, 1999; Wong, Westfall, Fedan & Fleming, 1981).  There are two 
main contributors to basal membrane potential: the diffusion potential, of which the outward 
diffusion of K+ is the main component, and the electrogenic activity of the Na+/K+ ATPase.  Of 
these two contributors, it was determined that the Na+/K+ ATPase was responsible for the 
adaptive partial depolarization observed in tolerant myenteric neurons (Kong, Leedham, Taylor 
& Fleming, 1997; Leedham, Kong, Taylor, Johnson & Fleming, 1992).  The proposed 
mechanism by which the Na+/K+ ATPase contributes to morphine’s activity on neurons involves 
the activation of the µ receptor by morphine which inhibits adenylyl cyclase and decreases PKA 
activation, leading to a decrease in the level of phosphorylation at Na+/K+ ATPase α3 subunit, 
increasing its activity (Blanco & Mercer, 1997; Masocha, González, Baeyens & Agil, 2002; Wu, 
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Li, Chen, Chi & Liu, 2006).  The increase in activity contributes to the overall hyperpolarization 
produced by µ receptor activation. 
The Na+/K+ ATPase is composed of two subunits, an α subunit which contains the binding 
sites for Na+ and K+ as well as cardiac glycosides such as ouabain, and a β subunit which is 
responsible for trafficking and insertion into the membrane (Sweadner, 1989).  There are four α 
subunits: the α1 subunit is expressed ubiquitously, the α2 subunit is mainly found in muscle and 
the nervous system, the α3 subunit is expressed predominately in neurons, and the α4 subunit 
which is expressed only in the testis (Tokhtaeva, Clifford, Kaplan, Sachs & Vagin, 2012).  There 
are three β subunits: the β1 subunit is expressed ubiquitously, the β2 subunits are expressed 
mainly in skeletal muscle and brain, and the β3 subunit is found in the testis, skeletal muscle, 
lung, and liver (Tokhtaeva, Clifford, Kaplan, Sachs & Vagin, 2012).  The α3β1 subunit 
combination has been implicated in the action of cardiac glycosides and is a form of the sodium 
pump thought to be specific to neurons (Schwinger et al., 1999). 
After chronic morphine treatment, there is some debate as to the nature of the adaptation that 
occurs.  In the LM/MP it has been shown that there is a decrease in the α3 subunit that correlates 
with the development of tolerance in that tissue, but not in the α1 subunit (Li, Maguma, Thayne, 
Davis & Taylor, 2010).  In agreement with this finding it was also shown by another laboratory 
that there was about a 40% decrease in the abundance of the α3 subunit found in the 
synaptosomes isolated from the cerebral cortex of morphine tolerant rats (Prokai, Zharikova & 
Stevens, 2005).  Other authors observed a decrease in the activity of the pump, specifically the α3 
subunit, without a decrease in the protein level (Gonzalez et al., 2012).  It has been suggested 
that the cause of this discrepancy may be due to differences in the way different tissues develop 
tolerance (Gonzalez et al., 2012).  Activation of PKC leads to a decrease in the activity of the 
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α3β1 subunit combination as well as others (Blanco & Mercer, 1997).  As stated in previous 
sections, some of the adaptations that occur with chronic morphine exposure are enhanced 
activation of PKA and PKC, both of which can negatively modulate Na+/K+ ATPase activity by 
altering its phosphorylation state.  As such, this may explain the decrease in activity noted by 




Table 1.1 Common Opioid Drugs 
This table lists a number of the opioid agonists and antagonists with their selectivity for the main 
three receptor types.  This table was adapted from (Yaksh & Wallace, 2011).  aµ-preferring; bδ-
preferring; cκ-preferring; dUniversal ligand; eIrreversible ligand; + = agonist; - = antagonist; P = 
partial agonist.  The greater the number of symbols, the greater the potency.  The ratio of these 
symbols is representative of the selectivity of these agents.  The values were calculated from in 
vivo/in vitro animal pharmacological work and may not extrapolate to humans.  
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 Opioid Receptor Types 
Agonists µ δ κ 
Morphinea +++  + 
Etorphine +++ +++ +++ 
Fentanyl +++   
Hydromorphone +++  + 
Methadone +++   
Sufentanil +++ + + 
DAMGOa ([D-Ala2, MePhe4, Gly(ol)5]enkephalin) +++   
DPDPEb ([D-Pen2, D-Pen5]enkephalin)  ++  
Bremazocine +++ ++ +++ 
Buprenorphine P  -- 
Butorphanol P  +++ 
Ethylketocyclazocine P + +++ 
Nalbuphine --  ++ 
Spiradolinec +  +++ 
    
Antagonists µ δ κ 
Naloxoned --- - -- 
Naltrexoned --- - --- 
CTOPa ---   
Diprenorphine --- -- --- 
β-Funaltrexaminea,e --- - ++ 
Naltrindoleb - --- - 




Table 1.2: Summary of central and peripheral effects caused by opioid agonists 
This table, adapted from (Al-Hasani & Bruchas, 2011) summarizes the effect an opioid agonist 
has on various organ systems.  
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Analgesia Rate of respiration 
Euphoria Cough reflex 
Sedation  
Miosis-Constriction of pupils  
Truncal Rigidity  
Nausea and vomiting  
   
Gastrointestinal 
System 
Constipation Gastric motility 
Constriction of biliary smooth muscle Digestion in the small intestine 
Esophageal reflux Peristaltic waves in the colon 
   
Other Smooth 
Muscle 
Depression of renal function Uterine tone 
Urinary retention  
   
Skin 
Itching and sweating  
Flushing of the face, neck, and thorax  




Blood pressure and heart rate if 
cardiovascular system is stressed 
   
Immune System 
 
Formation of rosettes by human 
lymphocytes 
 





Table 1.3 Selected Endogenous Opioid Peptide Sequences 
This table contains the sequences for some of the common opioid peptides from each class.  For 
each peptide the opioid motif is bolded and the selectivity is noted.  This table is adapted from 
Table 18-1 found in (Yaksh & Wallace, 2011).  + = agonist; - = antagonist; P = partial agonist. 
The greater the number of symbols, the greater the potency.  The ratio of these symbols is 
representative of the selectivity of these agents.  The values were calculated from in vivo/in vitro 
animal pharmacological work and may not extrapolate to humans.  
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  Receptor type 
Peptide Name Sequence Mu (µ) Delta (δ) Kappa (κ) 
Met-enkephalin (Tyr-Gly-Gly-Phe-Met) ++ +++  

























Figure 1.1 Chemical Structure of Morphine 









Figure 1.2 Acute mu opioid receptor signaling 
This figure is a schematic representation of the signaling consequences that result from acute mu 







Figure 1.3 Mu receptor function at pre- and post-synaptic neurons 
This figure depicts the effect of mu receptor activation on both pre- and post-synaptic neurons.  
Receptor activation on pre-synaptic neurons prevents release of neurotransmitter while post-
synaptic neurons are hyperpolarized.  Drawn by Kathleen Thayne, based on information found in 






Figure 1.4 Sites of Opioid Action that Produce Analgesia 
Opioids act in the periphery and at the “pain gate” neurons in the dorsal horn of the spinal cord.  
If the neurons in the dorsal horn of the spinal cord do not fire action potentials, the pain signal 
does not get transmitted to the brain and the sensation of pain is not experienced by the person.  
Opioids also enhance the activity of descending inhibitory pathways that dampen transmission of 
pain signals at the dorsal horn.  Drawn based on information found in (Fields & Basbaum, 2005).  
PAG = periaqueductal gray; NRM = nucleus raphe magnus; NRPG = nucleus reticularis 






Figure 1.5 Sites of Phosphorylation on the Rat µ receptor 
This figure was adapted from figure 1 found in the review article by (Allouche, Noble & Marie, 
2014).  This figure shows some of the sites that the rat µ receptor is phosphorylated at under 
basal conditions as well as sites that are phosphorylated after exposure to agonists.  In cases 
where it is known, the kinase(s) that mediates the phosphorylation of each site is shown.  For 







Figure 1.6 Mechanisms of Opioid Desensitization 
This figure was adapted from figure 2 found in the review article by (Allouche, Noble & Marie, 
2014).  This figure depicts the arrestin dependent form of desensitization of the µ receptor that is 
seen with DAMGO exposure and the arrestin independent form that results in very little receptor 









CHAPTER TWO: MATERIAL AND METHODS 
2.1 Animals 
All experimental procedures employing animals were reviewed and approved by the 
Institutional Animal Care and Use Committee of the Brody School of Medicine at East Carolina 
University and were conducted in accordance with the guidelines for the humane use of animals 
in research [NIH “Public Health Service Policy on Humane Care and Use of Laboratory 
Animals” (revised 2011)].  Dunkin-Hartley guinea pigs (Charles-River labs; Raleigh, NC, USA) 
of either sex weighing 200–450g were used in the study.  The animals were housed 4 per cage 
with access to food and water ad libitum.  The guinea pigs were kept in the animal facility for 1 
week to permit acclimation prior to initiation of any treatment.  Every effort was made to reduce 
the use of animals to the minimum number required to achieve sufficient statistical power. 
2.2 Drugs 
Morphine sulfate pentahydrate, ([D-Ala2, MePhe4, Gly(ol)5]enkephalin) DAMGO, 2-
chloroadenosine (2-CADO), and nicotine hydrogen tartrate salt were purchased from Sigma 
Chemical Company (St. Louis, MO). The dose of all drugs was corrected to exclude the 
conjugated salt.  Isoflurane was purchased from the Department of Comparative Medicine at 
East Carolina University. 
2.3 Animal Treatment 
Animals were treated using a subcutaneous or intraperitoneal injection schedule adapted 
from Li et. al (Li, Maguma, Thayne, Davis & Taylor, 2010).  Drugs or vehicle were injected in 
the housing room of the animal facility.  For intraperitoneal injections animals were wrapped in 
cloth such that their front paws were restricted and they could not see the needle.  Because the 
animals resist subcutaneous injections, risking injury to themselves during the process and 
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commercially available restrainers did not adequately restrain animals as small as those that we 
were using, a custom restrainer made from PVC pipe was used to prevent the animal from 
thrashing around during the injection procedure.  The restrainer itself is simply a PVC pipe with 
one end capped off.  A hole was cut into the top to allow access to the nape of neck of the 
animals.  Depending on the size of the animal additional pieces of pipe were used to raise the 
animal closer to the hole in the pipe.  Once the animal was inside a stopper obtained from a 
commercially available restrainer was placed inside the open end to prevent the animal from 
escaping.  With the restrainer the animals were not able to move forward or backwards and their 
side to side movement was minimal.  Drugs were injected twice daily at approximately 10:00 
AM and 10:00 PM.  The injections were made in the peritoneal cavity (intraperitoneal) or at the 
nape of the neck (subcutaneous) using a standard 1 mL tuberculin syringe with a 25 gauge needle 
obtained from the medical storeroom at East Carolina University Brody School of Medicine.  In 
an attempt to minimize the amount of inflammation due to repeated injections, the site of 
injection was randomized.  Occasionally on some of the older animals, the hair at the back of the 
neck was long enough to make it difficult to inject the animal.  To prevent this from being an 
issue the hair at the back of the neck was shaved.  Treated animals received morphine (free base) 
according to the following schedule: 10 mg/kg on day 1, 20 mg/kg on days 2 and 3, 40 mg/kg on 
days 4-7, and 80 mg/kg on days 8-10.  Placebo animals received an equivalent volume of saline 
based on the weight of the animal. To examine the onset of tolerance animals were treated for 1, 
2, 4, 7, or 10 days and assessed for tolerance 0 days after the last full treatment day.  To examine 
the decay of heterologous tolerance animals that were treated for 4, 7, and 10 days were assessed 
for tolerance 1, 2 or 4 days after the last full treatment day.  All experiments were done with 
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pairs of animals (1 morphine treated and 1 placebo treated) in order to account for some of the 
daily variability that may occur with paw pressure testing and/or the organ bath experiments.  
2.4 Randal-Selitto Paw Pressure Test 
Behavior assessment was performed early on the day of the experiment.  Each animal was 
acclimated to the observation room for 1 h prior to the initiation of any assessment.  Although it 
was discovered after these experiments were performed, this acclimation period should be 
sufficient to prevent any stress related analgesia by exposure to male experimenters according to 
Sorge et al. (Sorge et al., 2014).  The Randall and Selitto (1957) test was used to assess 
mechanical nociception (Randall & Selitto, 1957).  In this test, pressure was manually applied to 
the plantar surface of the hind paw using a cone-shaped pusher with a rounded tip (Randall-
Selitto analgesimeter model 2500 [IITC Life Sciences, Woodlands Hills, CA]) (see figure 2.2).  
Pressure was applied gradually until the guinea pig either vocalized or withdrew its paw.  The 
force (in grams) at which the guinea pig withdrew its hind paw or vocalized was defined as the 
paw pressure threshold.  A cut-off was set at 600 grams of pressure to prevent tissue damage.  
Baseline analgesia was determined prior to injecting the challenge drug.  Subsequent mean 
response thresholds were determined at the following time intervals after acute drug 
administration: 15, 30, 45, 60, and 90.  Occasionally the test was performed at 120 minutes after 
the challenge dose if the animal’s response was still not back to baseline.  Tolerance was defined 
as a reduction in the antinociceptive effect (decreased threshold for withdrawal) of the challenge 
dose of agonist such that the maximum amount of pressure required to elicit a paw withdrawal 
was decreased.  The challenge dose employed (morphine, 10 mg/kg s.c.) was selected based on 
preliminary studies done to assess the optimum dose required to produce an adequate and 
quantifiable analgesic response.  The magnitude of the tolerance that developed was assessed by 
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calculating the area under the curve (AUC) for the time versus pressure threshold graphs using 
Graph Pad Prism 5.  There was no apparent difference in locomotor activity displayed by the 
subjects in the treatment group in response to the acute drug administration. 
2.5 Longitudinal Smooth Muscle/Myenteric Plexus Preparations 
The LM/MP from morphine treated and placebo animals was used as an ex-vivo model to 
assess tolerance. The procedure to remove and isolated LM/MP segments was established 
previously by Paton (Paton, 1957).  Animals were euthanized by decapitation following 
isoflurane anesthesia.  The abdomen was opened to expose the cecum.   The 10 cm section of 
ileum closest to the cecum was removed and discarded, and 2–4 cm segments of ilea from the 
adjacent 10 cm of ileum (see figure 2.3) were used for the LM/MP preparations.  The segments 
of ilea were threaded on to a glass rod and, using a cotton swab moistened with Krebs–Henseleit 
buffer (see Appendix B), the LM/MP were carefully stripped tangentially from the point of 
mesenteric attachment until the muscle–nerve preparation was detached from the total area of the 
ileum. 
The resulting sheet of LM/MP was tied at each end with surgical silk, passed through 
platinum-ring electrodes, and placed in a 10-ml organ bath containing Krebs-Henseleit buffer 
solution.  One thread was tied to a Grass FT.03 force transducer and the other fixed to a tissue 
holder on the electrode, making sure that the thread was not touching the sides of the organ bath 
and as close to the center as possible (see figure 2.1).  The output of the force transducer was 
delivered to a computer and digitized using the Power Lab/Chart 7 computer program (AD 
Instruments, Colorado Springs, CO, USA) through a four channel power lab system using a four 
channel Quad bridge converter interface (AD instruments, Colorado Springs, CO, USA).  Force 
transducers were calibrated with a 1 g weight prior to attaching the tissues and electrodes.  Two 
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tissues from each animal were placed in organ baths for these experiments. In order to control for 
the variation in organ bath temperature due to the distance away from the water bath as well as 
other factors associated with placement in the organ baths, the morphine and placebo tissues 
were alternated with each experiment such that for a given time point there were experiments in 
which the morphine tissues were closest to the water bath and vice versa. 
The tissues were maintained at 37˚C in a physiological Krebs-Henseleit buffer solution (see 
Appendix B) bubbled continuously with a mixture of 95% O2/ 5% CO2.  A basal tension of 1.0 g 
was set for each tissue and isometric tension generated by the muscle was recorded and stored 
using the Power Lab/Chart 7 program.  Tissues were allowed to rest for 15 min before beginning 
neurogenic contractions.  Neurogenic contractions were elicited via transmural electrical 
stimulation using supramaximal voltage delivered to the tissue through platinum-ring electrodes 
using a stimulation system consisting of a Grass S48 stimulator connected to the electrodes by a 
Med Lab Attenuator and Stimu-splitter.  To ensure only nerve endings were stimulated, the 
following parameters were used: voltage (50V); impulse duration (<1 ms); delay setting (zero); 
and frequency (0.1Hz).  To allow for equilibration, the tissues were stimulated for 1 hour before 
exposure to inhibitory drugs.  During the equilibration period the buffer solution was replaced at 
15 min intervals.   
2.5.1 Ex-Vivo Assessment of Tolerance 
To assess tolerance in the LM/MP, concentration response curves were constructed by 
exposing the tissues to cumulatively increasing concentrations of the inhibitory drugs DAMGO 
and 2-CADO (final concentrations in the organ bath ranging between 1 nM and 10 μM) (see 
figure 2.4).  To minimize the impact of acute tolerance, the order the in which drugs were 
administered was randomized.  Three 5 min washes followed by three 15 min washes with drug 
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free Krebs–Henseleit solution were performed between concentration–response curves of 
different drugs permitting full recovery of the amplitude of neurogenic contractions.  In each 
experiment, two LM/MP preparations from each test group of animals were studied 
simultaneously and the responses of the tissues from the same animal averaged.  The Lab Chart 7 
software automatically constructed an average concentration response curve for each treatment 
group and calculated a number of parameters, including an IC50 value for each drug.  A daily 
morphine to placebo ratio of the –log (IC50) for DAMGO, 2-CADO, and in some cases nicotine 
was obtained from each pair of animals and used for statistical analysis. Graph Pad Prism 5® 
(Graph Pad Software, Inc.) was used for all statistical analyses. 
2.6 Tissue Preparation 
The LM/MP of both control and treated guinea pigs were removed as detailed in section 2.5.  
In addition to the LM/MP, the heart, diaphragm, and brain (sectioned into the cortex, midbrain, 
brainstem, and cerebellum) were also taken from the animals as soon as possible after 
euthanasia. The tissues that were not to be used immediately for the organ bath experiments were 
placed in labeled aluminum foils, frozen in liquid nitrogen, and stored at -80°C until they were 
used for western blot analysis.  For western blot analysis, tissues were homogenized and a 
protein assay was performed to determine the amount of protein in each sample after 
homogenization.   
2.6.1 Tissue Homogenization 
Tissues were removed from the -80°C freezer and weighed. An amount of protease inhibitor 
buffer (see Appendix C) was added to a ground glass homogenizer (PowerGen 125; Fisher 
Scientific, Pittsburgh, PA) depending on the wet weight of the tissue (1 mL of buffer per 100 mg 
of wet weight).  Tissues were then placed in the homogenizer and homogenized until there were 
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no visible pieces of tissue left. The homogenate was then placed into a 1.5 mL microcentrifuge 
tube and centrifuged for 5 seconds and maximum speed (14000 rpm).  The supernatant was 
transferred to a clean 1.5 mL microcentrifuge tube and spun for 10 minutes at maximum speed at 
4°C.  The supernatant was aliquoted into the necessary number of microcentrifuge tubes to 
ensure that there was only enough sample to be used for a protein assay and a western blot in 
each tube.  This process of preparation prevented wasting sample and reduced protein damage by 
excessive freezing and thawing of the sample.  The tubes were stored at -20°C for later use. 
2.6.2 BCA Protein Assay 
Spectrophotometric determination of protein concentration in samples was determined using 
a Pierce® BCA Protein assay kit (Pierce Biotechnology, Rockford, Illinois).  Bovine serum 
albumin (BSA) was made at a concentration of 1 mg per 1 mL of phosphate buffered saline (PBS 
– see Appendix D).  Serial dilutions (0.5, 0.25, 0.1, and 0.05 mg/mL) of this BSA solution were 
made to create the standard curve that was used extrapolate the protein concentration of the 
samples.  Samples were diluted 1:20 with PBS.  In a 96 well plate, 10 µL of the samples, the 
standards, and a blank (PBS) were loaded in triplicate.  200 µL of BCA dye reagent was added to 
each well and mixed. The dye reagent is made by mixing 50 parts dye reagent A with 1 part dye 
reagent B and should be green in color.  In the presence of protein, the dye should change from 
green to purple.  The reaction will occur at room temperature, but to increase the reaction rate the 
plate was incubated at 37°C for 15 minutes.  If the color had not developed sufficiently after 15 
minutes, the plate was incubated for another 15 minutes. The absorbance of each well at a 
wavelength of 562 nm was read using the Infinite M200 PRO plate reader (Tecan US, Research 
Triangle Park, NC).  Calculation of the standard curve and interpolation of concentration of the 
samples were done using Graph Pad Prism 5 software. 
52 
 
2.7 Western Blot 
To assess the relative abundance of specific proteins in each sample, western blots were 
performed.  Prior to western blotting, the samples to be examined were homogenized and the 
concentration of total protein in each sample was determined using a BCA protein assay as 
detailed in section 2.6.  The protocol for western blotting was similar to one that was used in the 
lab previously by Biser et al (Biser, Thayne, Fleming & Taylor, 2002).  Tissue homogenates 
were diluted 1:1 with a working sample buffer solution (see Appendix D).  These samples were 
loaded onto a Bio Rad Criterion 10% TGX pre-cast polyacrylamide gel (Bio-Rad Laboratories, 
Inc., Hercules, CA) at a concentration of 20 µg of protein per well.  The concentration of protein 
per well was determined based on preliminary experiments and was deemed suitable to detect the 
proteins of interest.  In addition, each gel was also loaded with 3 µL of the Kaleidoscope ladder 
(Bio-Rad Laboratories, Inc., Hercules, CA).  Samples were then size fractionated via 
electrophoresis at 200 V using a Criterion cell (Bio-Rad Laboratories, Inc., Hercules,CA).  
Proteins were transferred from the gel to a pre-made polyvinylidene fluoride (PVDF) membrane 
transfer pack from Bio-Rad using the Trans-Blot Turbo from Bio-Rad using the appropriate 
setting depending on the number of gels being run.  After transfer, membranes were 
prehybridized in Odyssey Blocking Buffer (Li-cor Biosciences, Lincoln, NE) overnight at 4°C.  
Following this step, the membranes were rinsed with phosphate buffered saline with 0.1 % 
Tween-20 (PBS-T, see Appendix D) and then washed 3 times for 15 minutes each with PBS-T.  
After washing, the primary antibody was added at the appropriate concentration for each protein 
of interest (see Appendix E for details).  Previous experiments were performed in order to 
optimize the antibody concentrations for each protein of interest (see figures 2.5-2.13).  Primary 
antibody incubation lasted 1 hour. After primary antibody incubation the membrane was washed 
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3 times with PBS-T for 10 minutes each.  Following these washes, the secondary antibody was 
added at previously optimized dilutions (see Appendix E) for 1 hour. After secondary antibody 
incubation, the membrane was washed 4 times for 10 minutes with PBS (not PBS-T).  
Membranes were allowed to dry completely before imaging with the Odyssey CLX® near-
infrared imaging system (Li-Cor Biosciences, Lincoln, NE).  Densitometry analysis was 
performed using the Image Studio 5.2 software (Li-Cor Biosciences, Lincoln, NE). 
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Figure 2.1 Anatomy of the Ileum 
Most of the tissue work was done in this project using the outermost layer of the ileum consisting 
of the longitudinal smooth muscle and the myenteric plexus.  The next layer going inward is the 






Figure 2.2 Randall-Selitto Analgesimeter 2500 
In the context of the paw pressure test this device measures and records the amount of force 
required to cause pain great enough to elicit a paw withdraw response from the animal.  The hind 
paw of the guinea pig is placed in the apparatus such that the rubber cone will press down on the 
plantar surface.  Force is manually applied and increased gradually until the animal feels pain 







Figure 2.3 Organ Bath Schematic Diagram 
Schematic diagram depicting the organ bath set up used to obtain concentration response curves 








Figure 2.4 Representative tracing depicting the concentration dependent reduction in the 
amplitude of neurogenic twitches of the LM/MP. 
A) In this tracing the LM/MP was exposed to cumulatively increasing concentrations of the 
inhibitory drug DAMGO (final cumulative concentration in the bath ranging between 1 nM and 
3 µM).  The effect of DAMGO on the neurogenic twitches is calculated as a percent inhibition of 
the initial amplitude.  IC50s are defined here as the concentration of drug required to reduce the 
amplitude of the contractions by 50%. 
B)  A continuation of the tracing in A depicing the return of the electrogenic twitches after 










Figure 2.5 Verification of µ opioid receptor antibody 
A representative image of a western blot using LM/MP homogenates from a naïve guinea pig 
and brainstem homogenates from a placebo treated guinea pig using the antibody concentration 
displayed in Appendix E and following the protocol described in section 2.7.  The µ receptor 
appears at 45 kDa in the 680 nM channel (red) and the housekeeper protein, GAPDH, is shown 






Figure 2.6 Verification of Adenosine 1 (A1) receptor antibody 
A representative image of a western blot using LM/MP homogenates from a naïve guinea pig 
and brainstem homogenates from a placebo treated guinea pig using the antibody concentration 
displayed in Appendix E and following the protocol described in section 2.7.  The A1 receptor 
appears at 45 kDa in the 680 nM channel (red) and the housekeeper protein, GAPDH, is shown 






Figure 2.7 Verification of Adenosine 2a (A2a) receptor antibody 
A representative image of a western blot using LM/MP homogenates from a naïve guinea pig 
and brainstem homogenates from a placebo treated guinea pig using the antibody concentration 
displayed in Appendix E and following the protocol described in section 2.7.  The A2a receptor 
appears at 45 kDa in the 680 nM channel (red) and the housekeeper protein, GAPDH, is shown 







Figure 2.8 Verification of Alpha 2b Adrenergic (α2b) receptor antibody 
A representative image of a western blot using LM/MP homogenates from a naïve guinea pig 
and brainstem homogenates from a placebo treated guinea pig using the antibody concentration 
displayed in Appendix E and following the protocol described in section 2.7.  The α2b receptor 
appears at 45 kDa in the 680 nM channel (red) and the housekeeper protein, GAPDH, is shown 






Figure 2.9 Verification of PKCγ antibody 
A representative image of a western blot using LM/MP homogenates from a naïve guinea pig 
and brainstem homogenates from a placebo treated guinea pig using the antibody concentration 
displayed in Appendix E and following the protocol described in section 2.7.  The PKCγ appears 
at 45 kDa in the 680 nM channel (red) and the housekeeper protein, GAPDH, is shown in the 






Figure 2.10 Verification of PKCε antibody 
A representative image of a western blot using LM/MP homogenates from a naïve guinea pig 
and brainstem homogenates from a placebo treated guinea pig using the antibody concentration 
displayed in Appendix E and following the protocol described in section 2.7.  The PKCε appears 
at 45 kDa in the 680 nM channel (red) and the housekeeper protein, GAPDH, is shown in the 







Figure 2.11 Verification of Na+/K+ ATPase α1 antibody 
A representative image of a western blot using LM/MP homogenates from a naïve guinea pig 
and brainstem homogenates from a placebo treated guinea pig using the antibody concentration 
displayed in Appendix E and following the protocol described in section 2.7.  The α1 subunit of 
the Na
+/K+ ATPase appears at 45 kDa in the 680 nM channel (red) and the housekeeper protein, 









Figure 2.12 Verification of Na+/K+ ATPase α3 antibody 
A representative image of a western blot using LM/MP homogenates from a naïve guinea pig 
and brainstem homogenates from a placebo treated guinea pig using the antibody concentration 
displayed in Appendix E and following the protocol described in section 2.7.  The α3 subunit of 
the Na
+/K+ ATPase appears at 45 kDa in the 680 nM channel (red) and the housekeeper protein, 






Figure 2.13 Verification of Na+/K+ ATPase β1 antibody 
A representative image of a western blot using LM/MP homogenates from a naïve guinea pig 
and brainstem homogenates from a placebo treated guinea pig using the antibody concentration 
displayed in Appendix E and following the protocol described in section 2.7.  The β1 subunit of 
the Na
+/K+ ATPase appears at 45 kDa in the 680 nM channel (red) and the housekeeper protein, 










CHAPTER THREE: TIME COURSE FOR THE ONSET AND DECAY OF 
HETEROLOGOUS TOLERANCE TO MORPHINE INTRAPERITONEALLY 
INJECTED INTO GUINEA PIGS 
3.1 Abstract 
It is believed that opioid tolerance results from adaptive changes in cellular signaling 
pathways associated with the µ opioid receptor.  The adaptive changes develop in these signaling 
elements as the changes in function occur and should reverse as the function returns to normal.  
The extent of these changes should be proportional to the magnitude of tolerance that develops.  
More extensive adaptations resulting from a greater magnitude of tolerance require longer 
periods of time to reverse after dosing stops and function returns to normal.  To test these 
hypotheses it is necessary to have a complete time course for the development and decay of 
tolerance to morphine.  Previous work has established a time course for the onset of tolerance in 
guinea pigs implanted with morphine pellets.  However, this method of administration is not 
adequate to examine the decay of tolerance because a time zero cannot be established due to the 
uncertainty surrounding the exact time when morphine has left the pellet.  To establish a 
complete time course a parenteral injection administration protocol would be more appropriate 
because the time when dosing stops can be controlled and identified more accurately.  Therefore, 
guinea pigs were treated with bi-daily intraperitoneal injections of escalating doses of morphine 
for 4, 7, or 10 days to induce tolerance.  Tolerance was then assessed at 0, 1, 2, or 4 days after 
treatment cessation via paw pressure testing in the whole animal and by measuring the 
responsiveness of the LM/MP to nicotine, DAMGO, and 2-CADO ex-vivo.  The results of these 
experiments were subject to higher variability than that reported for either subcutaneous or pellet 
implantation administrations which prevented the achievement of statistical significance.  This 
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variability was attributed to variable absorption and/or metabolism of the drug due to the route of 
administration.  Intraperitoneal injections allow the drug to be subjected to first pass hepatic 
metabolism.  Paw pressure results indicated no changes between morphine and placebo animals 
regardless of treatment length.  After further examination it was determined that the lack of 
responsiveness was due to using 10 mg/kg of morphine sulfate pentahydrate. Despite the lack of 
statistical significance in the whole animal studies, a trend for the IC50 of DAMGO and 2-CADO 
to be significantly greater in animals treated for 4, 7, or 10 days was observed in the LM/MP.  
For animals treated for 4 days, only 1 day was required to return the morphine to placebo ratio of 
the IC50s of DAMGO and 2-CADO back to ~1 after treatment ceased.  This took 2 days for the 7 
and 10 day treated animals.  No statistically significant results or trends were obtained with 
nicotine contractions in the LM/MP.  These results suggest that intraperitoneal injection is not 
the optimal route of administration to study the onset and decay of tolerance to morphine.  
3.2 Introduction 
Despite many years of research, the mechanisms underlying the development of tolerance to 
morphine are still not fully understood.  Tolerance is defined as the loss of responsiveness to a 
given agent that occurs as a result of repeated exposure to that agent.  Multiple forms of 
tolerance are known to exist and can be expressed independently or simultaneously (Johnson & 
Fleming, 1989).  The general consensus is that tolerance to morphine is an adaptive response that 
occurs due to chronic exposure to morphine.  As discussed in section 1.6, there are many 
different hypotheses regarding the mechanism(s) by which opioids, morphine in particular, 
develop tolerance.  In order for any of these proposed mechanisms to truly account for the 
observed changes in responsiveness, they must meet five criteria: “The proposed cellular change 
must: 1) be induced by experimental procedures identical to those that induce tolerance and/or 
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dependence; 2) follow a similar time course as the tolerance and/or dependence in that tissue; 3) 
quantitatively account for the tolerance and/or dependence; 4) account for the qualitative 
characteristics of the tolerance and/or dependence; and 5) occur in the very cells upon which the 
opioid is acting (Taylor & Fleming, 2001)”.  Of the model animals that are commonly used to 
study morphine tolerance guinea pigs were chosen.  There are several reasons for this choice.  
Firstly, guinea pigs have a distribution of opioid receptors in the brain that is much more similar 
to that of humans than of the other commonly used animals (Mansour, Khachaturian, Lewis, 
Akil & Watson, 1988).  In addition, guinea pigs display a pharmacological response to morphine 
that is more similar to humans than that observed in mice or rats.  Furthermore, like humans, 
guinea pigs do not display a motor response to morphine (Bot, Chahl, Brent & Johnston, 1992).  
Guinea pigs also allow access to the LM/MP model system that has been used since the 1970s to 
evaluate the characteristics and mechanism of tolerance to morphine (Goldstein & Schulz, 1973). 
Over the past several years this laboratory has focused on studying the second criteria.  Since 
tolerance develops over time, any adaptive change that occurs as a result of chronic morphine 
exposure should occur along a similar time course as the observed changes in function.  
Conversely, when chronic morphine exposure ends, the adaptation(s) should spontaneously 
reverse over a similar time course as the changes in function.  A time course for the onset of 
tolerance has been developed using pellet implanted guinea pigs (Barrett, Maguma & Taylor, 
2011; Li, Maguma, Thayne, Davis & Taylor, 2010).  While using pellet implanted animals does 
allow for adequate study of the development of tolerance, the decay of that tolerance cannot be 
accurately assessed because of the time at which the morphine has completely diffused out of the 
pellet cannot be ascertained; therefore a time zero for the initiation of the decay cannot be 
defined.  To study the decay of tolerance, a parenteral method of administration would be more 
83 
 
adequate.  It has already been shown that subcutaneous injection and pellet implantation 
administrations both develop a tolerance that is quantitatively and qualitatively similar (Li, 
Maguma, Thayne, Davis & Taylor, 2010).  Intraperitoneal injections have not been used to 
chronically treat animals with morphine.  The main goal of this work was to establish a time 
course for the onset and decay of tolerance to morphine in the guinea pig using intraperitoneal 
injections.  One hypothesis for this work is that chronic morphine treatment via intraperitoneal 
injection would produce a tolerance that is quantitatively and qualitatively similar to 
subcutaneous injection and/or pellet implantation.  A second hypothesis is that the decay of 
tolerance will be proportional to the magnitude of tolerance that develops.  The basis for these 
hypotheses lies in the fact that it has already been established that morphine administration by 
various methods all produced a tolerance that is similar in magnitude (Li, Maguma, Thayne, 
Davis & Taylor, 2010).  It is expected that a greater magnitude of tolerance is the result of more 
extensive adaptive changes and that it will take longer to reverse. 
3.3 Experimental Protocol 
All of the methods used here are detailed in chapter 2.  Dunkin-Hartley guinea pigs were 
treated via intraperitoneal (IP) injection for either 4, 7, or 10 days with either morphine sulfate 
pentahydrate or saline.  The dosing schedule employed (see table 3.1) was adapted from previous 
work in this laboratory (Li, Maguma, Thayne, Davis & Taylor, 2010).  Some of the animals for 
each of the treatment lengths were allowed to remain in the animal facility for specified lengths 
of time after the last dose of morphine in order to assess the decay of the developed tolerance.  
Animals treated for 4 days were assessed at 0, 1, or 2 days after the last treatment day.  Because 
it was expected that a greater degree of tolerance would take longer to fade, the animals treated 
for 7 or 10 days were assessed at 0, 2, or 4 days after the last treatment day.  To help control for 
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daily variations animals were dosed in pairs, a treated and a control, and a daily morphine to 
placebo ratio was calculated.  All statistics were done on these ratios.  For the sake of simplicity 
animals treated for 4 days and assessed 0 days after the last treatment day will be referred to as 4 
day – 0 day animals while animals treated for 4 days and assessed 1 day after the last treatment 
day will be referred to as 4 day – 1 day animals and so forth. 
Tolerance assessment consisted of paw pressure testing followed by euthanasia after 
isoflurane anesthesia.  At this point tissues were collected and segments of the LM/MP were 
prepared for the organ bath apparatus (see figure 2.3).  Because the nicotine concentration 
response curves needed to be done in the absence of electrical stimulation, non-cumulative 
nicotine concentration response curves were performed first.  After a washing period, electrical 
stimulation was applied and the tissue was allowed to reacclimate.  Cumulative concentration 
response curves for either DAMGO or 2-CADO (the order was randomized) were performed 
next, followed by a washing period and the concentration response curve for the other drug. 
All statistics were performed using Graph Pad Prism 5.  Two tailed T-tests were run to test 
whether or not the average morphine to placebo ratio was significantly different from unity.  
One-way ANOVAs were run to test for the differences in the average ratios between time points.  
Results were considered significant at a p value of less than 0.05. 
3.4 Experimental Results 
The paw pressure test was intended to be a measure of tolerance in the whole animal.  
However, we were able to detect no difference between placebo and morphine animals at any 
time point measured (see figures 3.1-3.3).  In the LM/MP, nicotine concentration response 
curves were generated and the EC50 and maximum contraction were calculated (see figures 3.4-
3.7).  No significant differences were detected at any time point for the EC50.  There was a 
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significant increase in the morphine to placebo ratio of the maximum response for 10 day – 2 day 
animals.  DAMGO and 2-CADO concentration response curves were also generated in the 
LM/MP for each sample (see figures 3.8-3.10).  There was a significant increase in the morphine 
to placebo ratio of the IC50s for both drugs at the 4 day – 0 day time points and the 10 day – 0 
day time points, indicating that the LM/MP was sub-sensitive to the inhibitory effects of both 
drugs at these time points.  Although it was not significant, there was a similar trend present for 
the 7 day – 0 day animals.  There was no significant difference in the morphine to placebo ratios 
of the IC50s of DAMGO or 2-CADO between the 4 day – 0 day, 7 day – 0 day, or 10 day – 0 day 
time points. 
3.5 Discussion 
The paw pressure analgesic test was intended to be a measure of tolerance in the whole 
animal and has been used in this lab previously with reasonable success (Barrett, Maguma & 
Taylor, 2011; Maguma & Taylor, 2011).  It was troubling that we obtained such poor results 
with the test.  Upon examination of the data, it was discovered that the problem was not that the 
morphine treated animals were not becoming tolerant to the drug, but rather it was that the 
placebo animals were not responding as robustly as that observed previously to the test dose of 
morphine used.  The dose used was 10 mg/kg; a standard dose that should have produced a 
measureable analgesic effect.  However, it was discovered that the dose employed was actually a 
10 mg/kg dose of morphine sulfate pentahydrate as opposed to a 10 mg/kg dose of morphine.  
Dosing of the animals was subject to the same error.  The result was that the animals were 
receiving a dose of morphine ~ 25% lower than what was planned.  This clearly had an impact 
on the paw pressure results.  However, even with a reduced dose, the animals were still receiving 
enough morphine to become tolerant to the effects of DAMGO and 2-CADO as early as 4 days 
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of treatment.  Although there was too much variability in the 7 day – 0 day LM/MP data to 
achieve statistical significance, there was no difference between the 4 day – 0day, 7 day – 0 day, 
and 10 day – 0 day morphine to placebo ratios of the IC50s of DAMGO and 2-CADO which 
implies that the same magnitude of tolerance had developed independent of treatment length.  
There was not a statistically significant difference at either the 4 day – 1 day or the 7 day – 2 day 
and the 10 day – 2 day time points, but it does appear that the concentration response curves for 
DAMGO and 2-CADO appeared similar.  Similarity also exists for the 4 day – 2 day, 7 day – 4 
day, and 10 day – 4 day curves.  These data may imply that despite a similar magnitude of 
tolerance, more extensive adaptations occurred in the 7 and 10 day treated animals that took 
longer to reverse. 
Nicotine was examined because previous work has suggested that neurons adapt to chronic 
morphine by becoming partially depolarized to compensate for the hyperpolarizing effect of 
morphine (Fleming, 1999; Taylor & Fleming, 2001).  In a partially depolarized state the neurons 
would be expected to be subsensitive to inhibitory agonists such as DAMGO and 2-CADO as 
well as supersensitive to excitatory agonists such as nicotine.  Indeed, it has been shown 
previously in the guinea pig LM/MP that chronic morphine treatment does induce 
supersensitivity to nicotine as well as other excitatory agonists (Barrett, Maguma & Taylor, 
2011; Johnson, Westfall, Howard & Fleming, 1978).  That finding could not be replicated in this 
study.  It may be worth pointing out that the method of administration in those studies in which 
supersensitivity to nicotine was observed was pellet implantation.  The difference in the method 
of administration may be important because it has been shown that pellet implantation does not 
cause as much stress on the animals as injections.  Both pellet implantation and subcutaneous 
injection of morphine acutely activate the hypothalamic-pituitary-adrenal (HPA) axis and 
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chronic exposure by either method results in tolerance to HPA axis effects (Sarnyai, Shaham & 
Heinrichs, 2001).  However, the difference between the two is that pellet implantation is 
considered to be a continuous exposure whereas injections are not.  It has been shown in rats that 
during the time between injections the animals undergo a partial withdrawal from the drug 
which, over the period of treatment, causes a state of constant stress (Houshyar, Gomez, Manalo, 
Bhargava & Dallman, 2003).  There is a connection between chronic activation of the HPA axis 
and the function of nicotine receptors (Lutfy et al., 2006) and it may be that the chronic stress 
state caused by the injection method of administration suppresses the supersensitivity of nicotine 
that was observed in the pellet implanted animals.  The lack of supersensitivity to nicotine does 
not necessarily imply that there is no generalized supersensitivity to excitatory stimuli in the 
LM/MP.  Although nicotine was the only agonist tested here, chronic morphine treatment also 
leads to supersensitivity of the LM/MP to 5-HT and K+ (Johnson, Westfall, Howard & Fleming, 
1978). 
This work was intended to elucidate the time course for the onset and decay of tolerance 
when using an IP injection administration protocol.  We were able to show that after 4 days of 
treatment a significant level of heterologous tolerance develops as evidenced by the increase in 
the IC50s values for DAMGO and 2-CADO in the LM/MP and that there is no difference 
between the magnitude of tolerance that develops between 4, 7, and 10 days of treatment.  
Despite there being no difference between the level of tolerance in these groups, the 7 and 10 day 
groups appear to take longer to return to baseline than the 4 day groups which implies that more 
extensive adaptations occurred in those groups.  We were unable to demonstrate supersensitivity 
to nicotine in the LM/MP, but this may be due to the manner in which morphine was 
administered.  Unfortunately due to the dosing error, the paw pressure testing revealed nothing in 
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the whole animal.  Also, there appears to be greater variability in the data generated here than in 
the data obtained following either pellet implantation or sc injection which prevented statistical 
significance in some of the groups in which trends were observed.  We believe the source of this 
variability to be the differential absorption of the drug from the mesenterium around the gut and 
hepatic metabolism.  For this reason, these data suggest that IP injection may not be the best 




Table 3.1 Injection Schedule 
This injection schedule was adapted from previous work in this lab (Li, Maguma, Thayne, Davis 
& Taylor, 2010).  Animals were treated with the doses of morphine sulfate pentahydrate or an 
equivalent volume of saline.  Some animals followed this schedule for only 4 days, some for 






Dose of Morphine 
Sulfate Pentahydrate 
1 10 mg/kg 
2 and 3 20 mg/kg 
4, 5, 6, and 7 40 mg/kg 





Figure 3.1 Paw Pressure Data for Animals Treated for 4 days 
A) Average paw pressure data for 4 day – 0 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.308 and was not significantly different from 1 (p value = 
0.0616). 
B) Average paw pressure data for 4 day – 1 day animals (n = 4).  The placebo to morphine ratio 
of the AUC = 1.160 and was not significantly different from 1 (p value = 0.1472). 
C) Average paw pressure data for 4 day – 2 day animals (n = 4).  The placebo to morphine ratio 






Figure 3.2 Paw Pressure Data for Animals Treated for 7 days 
A) Average paw pressure data for 7 day – 0 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.145 and was not significantly different from 1 (p value = 
0.2043). 
B) Average paw pressure data for 7 day – 2 day animals (n = 4).  The placebo to morphine ratio 
of the AUC = 0.994 and was not significantly different from 1 (p value = 0.9662). 
C) Average paw pressure data for 7 day – 4 day animals (n = 4).  The placebo to morphine ratio 






Figure 3.3 Paw Pressure Data for Animals Treated for 10 days 
A) Average paw pressure data for 10 day – 0 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.228 and was not significantly different from 1 (p value = 
0.1560). 
B) Average paw pressure data for 10 day – 2 day animals (n = 3).  The placebo to morphine ratio 
of the AUC = 1.291 and was not significantly different from 1 (p value = 0.1857). 
C) Average paw pressure data for 10 day – 4 day animals (n = 4).  The placebo to morphine ratio 







Figure 3.4 Nicotine Concentration Response Curves for Animals Treated for 4 days 
A) Average nicotine concentration response curve for 4 days – 0 day animals (n = 4).  The 
morphine to placebo ratio of the EC50 = 2.070 and was not significantly different from 1 (p value 
= 0.2459). 
B) Average nicotine concentration response curve for 4 days – 1 day animals (n = 4).  The 
morphine to placebo ratio of the EC50 = 1.175 and was not significantly different from 1 (p value 
= 0.2296). 
C) Average nicotine concentration response curve for 4 days – 2 day animals (n = 4).  The 
morphine to placebo ratio of the EC50 =1.888 and was not significantly different from 1 (p value 







Figure 3.5 Nicotine Concentration Response Curves for Animals Treated for 7 days 
A) Average nicotine concentration response curve for 7 days – 0 day animals (n = 4).  The 
morphine to placebo ratio of the EC50 = 1.279 and was not significantly different from 1 (p value 
= 0.4553). 
B) Average nicotine concentration response curve for 7 days – 2 day animals (n = 4).  The 
morphine to placebo ratio of the EC50 = 1.222 and was not significantly different from 1 (p value 
= 0.2895). 
C) Average nicotine concentration response curve for 7 days – 4 day animals (n = 4).  The 
morphine to placebo ratio of the EC50 = 1.327 and was not significantly different from 1 (p value 







Figure 3.6 Nicotine Concentration Response Curves for Animals Treated for 10 days 
A) Average nicotine concentration response curve for 10 days – 0 day animals (n = 4).  The 
morphine to placebo ratio of the EC50 = 1.155 and was not significantly different from 1 (p value 
= 0.3994). 
B) Average nicotine concentration response curve for 10 days – 2 day animals (n = 3).  The 
morphine to placebo ratio of the EC50 = 1.456 and was not significantly different from 1 (p value 
= 0.4275). 
C) Average nicotine concentration response curve for 10 days – 4 day animals (n = 4).  The 
morphine to placebo ratio of the EC50 = 1.233 and was not significantly different from 1 (p value 







Figure 3.7 Nicotine Maximum Response 
A) Average morphine to placebo ratios of the nicotine maximum response in the LM/MP for 
animals treated for 4 days and assessed 0, 1, or 2 days after the last treatment day (n = 4 for 
each).  The morphine to placebo ratios of the maximum response were 1.245, 1.584, and 0.886 
for the 4 day – 0 day, 4 day – 1 day, and 4 day – 2 day groups respectively. None of these ratios 
were significantly different from 1 (p values = 0.1041, 0.6355, and 0.3902 respectively). 
B) Average morphine to placebo ratios of the nicotine maximum response in the LM/MP for 
animals treated for 7 days and assessed 0, 2, or 4 days after the last treatment day (n = 4 for 
each).  The morphine to placebo ratios of the maximum response were 0.772, 0.869, and 0.763 
for the 7 day – 0 day, 7 day – 2 day, and 7 day – 4 day groups respectively. None of these ratios 
were significantly different from 1 (p values = 0.2762, 0.5668, 0.1518 respectively). 
C) Average morphine to placebo ratios of the nicotine maximum response in the LM/MP for 
animals treated for 10 days and assessed 0, 2, or 4 days after the last treatment day (n = 4 for 
each except the 10 day – 2 day group for which n = 3).  The morphine to placebo ratios of the 
maximum response were 0.872, 1.214, and 0.906 for the 10 day – 0 day, 10 day – 2 day, and 10 
day – 4 day groups respectively. Only the 10 day – 2 day morphine to placebo ratio was 
significantly different from 1 (p value = 0.0473).  The p values for the 10 day – 0 day and 10 day 







Figure 3.8 DAMGO and 2-CADO Concentration Response Curves for Animals Treated for 4 
days 
A)  Average DAMGO concentration response curve for 4 day – 0 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 4.578 and was significantly different from 1 (p value = 
0.0199). 
B)  Average DAMGO concentration response curve for 4 day – 1 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 1.222 and was not significantly different from 1 (p value 
= 0.3378). 
C)  Average DAMGO concentration response curve for 4 day – 2 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 1.359 and was not significantly different from 1 (p value 
= 0.4520). 
D)  Average 2-CADO concentration response curve for 4 day – 0 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 4.186 and was significantly different from 1 (p value = 
<0.0001). 
E)  Average 2-CADO concentration response curve for 4 day – 1 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 1.080 and was not significantly different from 1 (p value 
= 0.7497). 
F)  Average 2-CADO concentration response curve for 4 day – 2 day animals (n = 4).  The 









Figure 3.9 DAMGO and 2-CADO Concentration Response Curves for Animals Treated for 7 
days 
A)  Average DAMGO concentration response curve for 7 day – 0 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 3.160 and was not significantly different from 1 (p value 
= 0.0776). 
B)  Average DAMGO concentration response curve for 7 day – 2 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 1.857 and was not significantly different from 1 (p value 
= 0.0885). 
C)  Average DAMGO concentration response curve for 7 day – 4 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 0.964 and was not significantly different from 1 (p value 
= 0.8302). 
D)  Average 2-CADO concentration response curve for 7 day – 0 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 2.038 and was not significantly different from 1 (p value 
= 0.0754). 
E)  Average 2-CADO concentration response curve for 7 day – 2 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 1.466 and was not significantly different from 1 (p value 
= 0.4201). 
F)  Average 2-CADO concentration response curve for 7 day – 4 day animals (n = 4).  The 








Figure 3.10 DAMGO and 2-CADO Concentration Response Curves for Animals Treated for 10 
days 
A)  Average DAMGO concentration response curve for 10 day – 0 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 3.806 and was significantly different from 1 (p value = 
0.0402). 
B)  Average DAMGO concentration response curve for 10 day – 2 day animals (n = 3).  The 
morphine to placebo ratio of the IC50 = 1.259 and was not significantly different from 1 (p value 
= 0.2898). 
C)  Average DAMGO concentration response curve for 10 day – 4 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 1.387 and was not significantly different from 1 (p value 
= 0.3807). 
D)  Average 2-CADO concentration response curve for 10 day – 0 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 1.920 and was significantly different from 1 (p value = 
<0.0348). 
E)  Average 2-CADO concentration response curve for 10 day – 2 day animals (n = 3).  The 
morphine to placebo ratio of the IC50 = 0.752 and was not significantly different from 1 (p value 
= 0.3473). 
F)  Average 2-CADO concentration response curve for 10 day – 4 day animals (n = 4).  The 










CHAPTER FOUR: TIME COURSE FOR THE ONSET AND DECAY OF 
HETEROLOGOUS TOLERANCE TO MORPHINE SUBCUTANEOUSLY INJECTED 
INTO GUINEA PIGS 
4.1 Abstract 
The development and decay of heterologous tolerance following chronic morphine exposure 
via pellet implantation is well documented in the guinea pig longitudinal muscle/myenteric 
plexus (LM/MP).  However, this method of administration only permits a qualitative analysis of 
the decay phase of tolerance because the time at which morphine exposure is completed is 
unknown. IP administration of morphine was shown to be inadequate for time course studies due 
to variable absorption from the gut. Therefore, we assessed tolerance development in animals 
treated with twice daily subcutaneous injections of morphine for 1, 2, 4, 7, or 10 days.  The 
analgesic effect of morphine was assessed using the paw pressure test and the heterologous 
nature of tolerance evaluated using the neurogenic twitch inhibition of DAMGO and 2-CADO in 
the LM/MP.  Decay of tolerance was determined by evaluating animals or tissues from them 0, 
1, 2, or 4 days after treatment cessation.  A significant level of tolerance was generated by 2 days 
after treatment, which peaked at 4 days and was maintained through both 7 and 10 days of 
treatment.  The data indicated that the time for return to baseline was correlated to the magnitude 
of tolerance in all animal groups and was not significantly different by 2 days after treatment 
stopped in animals that were treated for 4 days and by 4 days in animals that were treated for 7 or 
10 days.  The fact that the decay of tolerance is a function of both the length of treatment and 
magnitude of tolerance developed reinforces the idea that tolerance following chronic treatment 
with morphine is an adaptive process produced by alterations in at least one of several possible 




Tolerance to opioids remains a problem for clinicians who use them to treat patients with 
severe chronic pain.  For decades researchers have sought to uncover the cellular mechanism(s) 
that underlie the development of tolerance to morphine.  With a mechanism identified, it would 
then be possible to develop drugs that could circumvent tolerance to morphine in the clinic.  It is 
widely believed that tolerance to opioids is the result of cellular adaptations to the prolonged 
exposure to the agonist.  There were five criteria proposed by Taylor and Fleming for a given 
cellular adaptation to account for the altered responsiveness that is observed in the tolerant state.  
The second of these criteria states that “the proposed cellular change must follow a similar time 
course as the development of tolerance and/or dependence in that tissue (Taylor & Fleming, 
2001)”.  The majority of work that exists in opioid research tends to focus on single time points, 
usually 7 days after treatment, when the animal is known to be tolerant to the drug used.  While 
this approach can yield important information about whether or not an adaptation exists, no 
information about when this change occurred or when/if it reverses once treatment ends can be 
obtained.  For a number of years this laboratory has focused on developing a time course for the 
onset and decay of tolerance to morphine.  Previous work has yielded such a time course in pellet 
implanted animals (Barrett, Maguma & Taylor, 2011; Li, Maguma, Thayne, Davis & Taylor, 
2010).  However, pellet implantation is inadequate for precisely examining the decay of 
tolerance because it is unknown when all of the morphine has diffused from the pellet and 
therefore a time zero for evaluation of the decay of tolerance cannot be defined.  Previous work 
had suggested that several different methods of inducing tolerance, pellet implantation and 
subcutaneous injection among others, produce a magnitude of tolerance that is indistinguishable 
from one another (Li, Maguma, Thayne, Davis & Taylor, 2010).  Work in chapter 3 sought to 
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add IP injection to this list while defining a time course for the onset and decay of tolerance.  
However it was discovered that IP injection led to higher variability in the data than the other 
methods and therefore is not the best choice for a time course study.  Because of the higher 
variability associated with IP injections, the time course study done in chapter 3 was repeated 
and expanded using subcutaneous injections.  Subcutaneous injection has already been used by 
the laboratory and shown to induce a tolerance that is similar in magnitude and character to that 
observed with pellet implantation.  Because animals that were treated for 4 days seemed to 
develop a magnitude of tolerance indistinguishable from animals treated for 7 or 10 days, 
animals that had been treated for 1 or 2 days and assessed immediately after the last treatment 
day were added to the study to better characterize the time of onset of tolerance.  Because the 
results of chapter 3 indicated that decay of tolerance for the 7 and 10 day treated animals 
progressed faster than originally hypothesized, to better characterize the decay of tolerance 
animals that were treated for 7 or 10 days and assessed 1 day after the last treatment day were 
added. 
4.3 Experimental Protocol 
All of the methods used here are detailed in chapter 2.  Dunkin-Hartley guinea pigs were 
treated via twice daily subcutaneous injections for 1, 2, 4, 7, or 10 days with either morphine 
(corrected for the free base) or saline.  The dosing schedule employed (see table 3.1) was adapted 
from previous work in this laboratory (Li, Maguma, Thayne, Davis & Taylor, 2010).  Some of 
the animals for each of the treatment lengths were allowed to remain in the animal facility for 
specified lengths of time after the last dose of morphine in order to assess the decay of the 
developed tolerance.  Animals treated for 1 or 2 days were assessed immediately after the last 
treatment day (0 days after).  Animals treated for 4 days were assessed at 0, 1, or 2 days after the 
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last treatment day.  Because it was expected that a greater degree of tolerance would take longer 
to fade, the animals treated for 7 or 10 days were assessed at 0, 1, 2, or 4 days after the last 
treatment day.  To help control for daily variations animals were dosed in pairs, a treated and a 
control, and a daily morphine to placebo ratio was calculated.  All statistics were done on these 
ratios.  For the sake of simplicity animals treated for 4 days and assessed 0 days after the last 
treatment day will be referred to as 4 day – 0 day animals while animals treated for 4 days and 
assessed 1 day after the last treatment day will be referred to as 4 day – 1 day animals and so 
forth. 
Tolerance assessment consisted of paw pressure testing followed by euthanasia after 
isoflurane anesthesia.  At this point tissues were collected and segments of the LM/MP were 
prepared for the organ bath apparatus (see figure 2.3).  After a washing period electrical 
stimulation was applied and the tissue was allowed to acclimate.  Cumulative concentration 
response curves for either DAMGO or 2-CADO (the order was randomized) were performed 
next, followed by a washing period and the concentration response curve for the other drug. 
All statistics were performed using Graph Pad Prism 5.  T-tests were run to test whether or 
not the average morphine to placebo ratio was significantly different from unity.  Results were 
considered significant at a p value of less than 0.05. 
4.4 Experimental Results 
4.4.1 Onset of Heterologous Tolerance 
Paw pressure testing in the whole animal revealed that the magnitude of tolerance that 
develops does indeed depend on the length of treatment (see figure 4.1; table 4.1).  A significant 
difference in the AUC was observed by as early as 2 days of treatment with ~1.5 fold increase in 
the placebo to morphine ratio of the AUC.  The magnitude of this shift increased with treatment 
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length, reaching a 2 fold increase in the AUC after 10 days of treatment.  Although the average 
AUC ratios for 4, 7, or 10 days of treatment were not significantly different from each other, it 
does appear that the longer the treatment, the greater the average AUC ratio.  These data were 
complemented by the organ bath data using LM/MP preparations obtained from these same 
animals.  The DAMGO IC50 data (see figure 4.2; table 4.1) mirror what was seen in the whole 
animal with paw pressure testing.  A 2 fold increase in the IC50 was observed after the second 
day of treatment.  After 4 days of treatment the shift had increased to ~2.7 fold.  A shift of 
similar magnitude was observed in the 7 and 10 day animals as well.  The development of 
heterologous tolerance (tolerance to 2-CADO stimulation of the A1 receptor) appears to lag 
behind tolerance to the µ receptor system and tolerance to the analgesic effect in the whole 
animal (see figure 4.3; table 4.1).  By the second day of treatment there was a non-significant 
(~1.8 fold) shift in the IC50 of 2-CADO.  A statistically significant shift in the 2-CADO IC50 
was not observed until 4 days of treatment (~2.7 fold increase).  A similar increase was also 
observed in the 7 and 10 day treated animals. 
4.4.2 Decay of Heterologous Tolerance 
Because heterologous tolerance was not observed in animals treated with morphine for 1 or 2 
days, no study of the decay of tolerance was necessary for these animals.  A significant level of 
tolerance was observed for all endpoints measured 1 day after treatment cessation in animals that 
had been treated for 4 days (see figures 4.4, 4.7, and 4.10; table 4.1).  By 2 days after treatment 
cessation in 4 day treated animals the LM/MP responses to DAMGO and 2-CADO had returned 
to baseline but there was still a significant level of tolerance present to the analgesic effect of 
morphine based on the increased AUC from the paw pressure test.  In animals that were treated 
for 7 days a significant level of tolerance exists to the inhibitory effects of DAMGO and 2-
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CADO up to 2 days after treatment cessation (see figures 4.8 and 4.11; table 4.1).  Although the 
paw pressure AUCs are not significantly increased at these time points (see figure 4.5; table 4.1), 
it is interesting to note that the magnitude of the change is the same as the 4 day post treatment 
AUC, which is significant.  The response of the LM/MP to DAMGO and 2-CADO returned to 
baseline by 4 days after treatment.  In animals that were treated for 10 days a significant level of 
tolerance to DAMGO in the LM/MP and to the analgesic effect of morphine, but not to 2-
CADO, was observed by 1 day post treatment (see figures 4.6, 4.9, and 4.12; table 1).  By 2 days 
after treatment cessation, only the analgesic effect of morphine in the paw pressure test 
demonstrated a significant level of tolerance which returned to baseline by 4 days after 
treatment. 
4.5 Discussion 
It is believed that heterologous tolerance results from adaptive changes in a number of 
intracellular proteins involved in regulating cell excitability.  This change in responsiveness 
should take time to be fully expressed as well as to return to normal after treatment has ceased.  
The second of five criteria that have been suggested to be fulfilled for a proposed cellular 
mechanism to account for any observed changes in responsiveness states that the change must 
occur over a similar time course as the change in responsiveness (Taylor & Fleming, 2001).  
Previous work from this laboratory has defined a time course for the onset and decay of tolerance 
both in the whole animal and in the LM/MP model system with pellet implanted animals 
(Barrett, Maguma & Taylor, 2011; Li, Maguma, Thayne, Davis & Taylor, 2010). However, 
because of the nature of the pellet implantation method of administration, an accurate time 
course for the decay of tolerance back to baseline could not be established in those studies.  This 
set of experiments are the first to attempt to examine the time course for the decay of tolerance in 
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detail.  The hypothesis being tested by these studies was that the magnitude to tolerance that 
develops should increase with treatment length and that a greater magnitude of tolerance should 
take longer to return to baseline.  In addition the time course for the development and decline of 
heterologous tolerance following chronic treatment with morphine should be similar in vivo and 
ex vivo.  Although there were some issues with the work from chapter 3, it was shown that the 
magnitude of tolerance that develops in the LM/MP when morphine is administered IP does 
depend on the length of treatment and that the decay time was also related to the length of 
treatment based on the fact that it takes longer for animals treated for 7 or 10 days to return to 
baseline than animals that were treated for 4 days (see chapter 3).  The same phenomenon was 
observed in these studies with subcutaneous administration of morphine.  In addition, with the 
dosing issue corrected, tolerance could be examined and observed to occur in the whole animal 
via paw pressure testing.  The data indicate that tolerance in the whole animal and in the LM/MP 
develops and decays over a similar time course.   
An interesting observation is that there was not a significant difference between the 
magnitude of tolerance that developed in the LM/MP between the 4, 7, and 10 day treated 
animals.  A similar relationship was observed in the IP treated animals as well and would imply 
that maximum tolerance in the LM/MP was achieved after only 4 days of treatment.  However, 
like the IP treated animals, it took longer for the observed tolerance in the 7 and 10 day animals 
to fade than in the 4 day animals (>2 days in the 7 and 10 day treated animals vs. 1 in the 4 day 
treated animals).  This would imply that despite the same magnitude of tolerance, more extensive 
cellular adaptations occurred in the animals treated for 7 or 10 days than in the 4 day treated 
animals.  This is consistent with data from many other laboratories that suggest that maximum 
tolerance in the LM/MP occurs after 7 days of treatment (Barrett, Maguma & Taylor, 2011; 
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Goldstein & Schulz, 1973; Leedham, Doak, Taylor & Fleming, 1989; Li, Maguma, Thayne, 
Davis & Taylor, 2010).  A similar phenomenon was observed in the paw pressure AUC ratios.  
However, despite the lack of a significant difference in the paw pressure AUC ratios of the 4, 7, 
and 10 day treated animals, a trend was present for an incremental increase as treatment length 
increased.  A greater increase in the AUC ratio may be more difficult to obtain using the 10 
mg/kg test dose of morphine in the paw pressure test in animals treated for longer than 10 days 
because that dose had almost no effect in the animals treated for 10 days (see figure 4.6).   
There are a few observations in the current experiments that could be improved upon.  The 
first is the fact that blood was not collected from any of the animals for measurement of 
morphine levels.  Morphine has a half-life of about 120 minutes (Trescot, Datta, Lee & Hansen, 
2008) but it has been reported that morphine levels could still be detected in urine 1 to 1.5 days 
after a dose is given (Vandevenne, Vandenbussche & Verstraete, 2000).  The latest that we still 
observed tolerance was 2 days after treatment cessation.  Plasma levels of morphine were not 
measured in these animals because there was no feasible way to do so at the time of these 
experiments.  As a result we cannot be certain that some of the observed effects of tolerance at 0 
or 1 day after treatment cessation were not simply due to the continued presence of morphine, 
especially with animals treated for 7 or 10 days, given our escalating dose schedule.  The fact 
that we still have a significant level of tolerance at 2 days after treatment cessation, a time when 
detectable levels of morphine should not be present in the plasma, in animals treated for 7 days 
would seem to indicate that tolerance has developed in these animals.  Another issue, which was 
actually raised concerning pellet implanted animals, is inflammation.  With pellet implanted 
animals there was some concern that the pellet implantation surgery produced inflammation 
around the surgery site that may have interfered with some of the measured endpoints and it was 
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suggested that an injection would reduce inflammation (Li, Maguma, Thayne, Davis & Taylor, 
2010).  To further minimize the impact of this potential confounding influences we injected at a 
different site, though still at nape of the neck, each time.  However, since some animals received 
injections 20 times in roughly the same area over 10 days, it is possible that there is still some 
influence of inflammation.  The IC50 data for DAMGO and 2-CADO and the paw pressure test 
were comparable to previous work in the laboratory, so we believe that there was, at most, the 
same level of inflammation if not less. 
With the time course for the development and decay of tolerance to morphine known, it is 
possible to correlate changes in protein expression to the observed changes in function.  Because 
receptor down-regulation could account for tolerance, one obvious choice for protein analysis is 
the µ receptor.  Other proteins such as the Na+/K+ ATPase and PKC have been suggested to play 
a role in the development of tolerance to morphine.  Tissues from the same animals that the 
functional responses were obtained in were used to examine the concentration of these and other 




Table 4.1 Summary of Onset and Decay of Tolerance Data 
For ease of comparison between time points, this table contains all of the placebo/morphine 
ratios of the AUC from the paw pressure experiments and the morphine/placebo ratios of the 
IC50s of DAMGO and 2-CADO in the LM/MP from all time points.  See figures 4.1-4.12 for 
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2.02 (0.245)* 1.48 (0.430) 1.21 (0.252)
1.24 (0.134) 0.74 (0.099) 0.774 (0.136)
1.45 (0.106)* 0.96 (0.301) 0.90 (0.320)
10 days
2.18 (0.054)* 2.70 (0.327)* 2.97 (0.407)*
1.43 (0.121)* 1.69 (0.118)* 2.22 (0.881)
7 days
1.92 (0.229)* 3.27 (0.452)* 2.98 (0.612)*
1.39 (0.139) 1.95 (0.348) 2.67 (0.652)
1.52 (0.220) 1.56 (0.163)* 1.66 (0.435)
4 days
1.70 (0.181)* 2.71 (0.403)* 2.66 (0.496)*
1.30 (0.092)* 2.60 (0.430)* 1.73 (0.141)*
1.33 (0.098)* 0.83 (0.164) 0.89 (0.204)
1.28 (0.097) 1.50 (0.231) 1.33 (0.200)
1.44 (0.114)* 2.03 (0.310)* 1.75 (0.322)
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Figure 4.1 Onset of Analgesic Tolerance in the Guinea Pig 
For all graphs, the green line represents the morphine treated group, while the black line is the 
placebo treated group 
A)  Average paw pressure data for 1 day – 0 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.279 and was not significantly different from 1 (p value = 
0.0639).   
B)  Average paw pressure data for 2 day – 0 day animals (n = 6).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.440 and was significantly different from 1 (p value = 
0.0141). 
C)  Average paw pressure data for 4 day – 0 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.695 and was significantly different from 1 (p value = 
0.0313). 
D)  Average paw pressure data for 7 day – 0 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.918 and was significantly different from 1 (p value = 
0.0279). 
E)  Average paw pressure data for 10 day – 0 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 2.180 and was significantly different from 1 (p value = 
0.0002). 
F)  Summary bar graph of the placebo to morphine ratio of the AUC from the data presented in 







Figure 4.2 Onset of Tolerance to DAMGO in the LM/MP 
For all concentration response curves: green line = morphine treated group, black line = placebo 
treated group. 
A)  Average DAMGO concentration response curve for 1 day – 0 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 1.503 and was not significantly different from 1 (p value 
= 0.0816).   
B)  Average DAMGO concentration response curve for 2 day – 0 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 2.027 and was significantly different from 1 (p value = 
0.0211). 
C)  Average DAMGO concentration response curve for 4 day – 0 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 2.708 and was significantly different from 1 (p value = 
0.0080). 
D)  Average DAMGO concentration response curve for 7 day – 0 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 3.266 and was significantly different from 1 (p value = 
0.0074). 
E)  Average DAMGO concentration response curve for 10 day – 0 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 2.698 and was significantly different from 1 (p value = 
0.0138). 
F)  Summary bar graph of the morphine to placebo ratios of the IC50s from the concentration 







Figure 4.3 Onset of Tolerance to 2-CADO in the LM/MP 
For all concentration response curves: green line = morphine treated group, black line = placebo 
treated group. 
A)  Average 2-CADO concentration response curve for 1 day – 0 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 1.328 and was not significantly different from 1 (p value 
= 0.1608).   
B)  Average 2-CADO concentration response curve for 2 day – 0 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 1.752 and was not significantly different from 1 (p value 
= 0.0669). 
C)  Average 2-CADO concentration response curve for 4 day – 0 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 2.657 and was significantly different from 1 (p value = 
0.0206). 
D)  Average 2-CADO concentration response curve for 7 day – 0 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 2.976 and was significantly different from 1 (p value = 
0.0319). 
E)  Average 2-CADO concentration response curve for 10 day – 0 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 2.965 and was significantly different from 1 (p value = 
0.0170). 
F)  Summary bar graph of the morphine to placebo ratios of the IC50s from the concentration 








Figure 4.4 Decay of Analgesic Tolerance in Guinea Pigs Treated for 4 Days 
For all graphs: green line = morphine treated group, black line = placebo treated group. 
A)  Average paw pressure data for 4 day – 0 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.695 and was significantly different from 1 (p value = 
0.0313). 
B)  Average paw pressure data for 4 day – 1 day animals (n = 6).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.293 and was significantly different from 1 (p value = 
0.0118). 
C)  Average paw pressure data for 4 day – 2 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.330 and was significantly different from 1 (p value = 
0.0436). 









Figure 4.5 Decay of Analgesic Tolerance in Guinea Pigs Treated for 7 Days 
For all graphs: green line = morphine treated group, black line = placebo treated group. 
A)  Average paw pressure data for 7 day – 0 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.918 and was significantly different from 1 (p value = 
0.0279). 
B)  Average paw pressure data for 7 day – 1 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.388 and was not significantly different from 1 (p value = 
0.0). 
C)  Average paw pressure data for 7 day – 2 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.520 and was not significantly different from 1 (p value = 
0.0777). 
D)  Average paw pressure data for 7 day – 4 day animals (n = 4).  The placebo to morphine ratio 
of the area under the curve (AUC) = 1.453 and was significantly different from 1 (p value = 
0.0233). 







Figure 4.6 Decay of Analgesic Tolerance in Guinea Pigs Treated for 10 Days 
For all graphs: green line = morphine treated group, black line = placebo treated group. 
A)  Average paw pressure data for 10 day – 0 day animals (n = 4).  The placebo to morphine 
ratio of the area under the curve (AUC) = 2.180 and was significantly different from 1 (p value = 
0.0002). 
B)  Average paw pressure data for 10 day – 1 day animals (n = 5).  The placebo to morphine 
ratio of the area under the curve (AUC) = 1.434 and was significantly different from 1 (p value = 
0.0233). 
C)  Average paw pressure data for 10 day – 2 day animals (n = 5).  The placebo to morphine 
ratio of the area under the curve (AUC) = 2.022 and was significantly different from 1 (p value = 
0.0141). 
D)  Average paw pressure data for 10 day – 4 day animals (n = 4).  The placebo to morphine 
ratio of the area under the curve (AUC) = 1.238 and was not significantly different from 1 (p 
value = 0.1737). 









Figure 4.7 Decay of Tolerance to DAMGO in the LM/MP of Guinea Pigs Treated for 4 Days 
For all concentration response curves: green line = morphine treated group, black line = placebo 
treated group. 
A)  Average DAMGO concentration response curve for 4 day – 0 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 2.708 and was significantly different from 1 (p value = 
0.0080).   
B)  Average DAMGO concentration response curve for 4 day – 1 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 2.597 and was significantly different from 1 (p value = 
0.0138). 
C)  Average DAMGO concentration response curve for 4 day – 2 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 0.830 and was not significantly different from 1 (p value 
= 0.3594). 
D)  Summary bar graph of the morphine to placebo ratios of the IC50s from the concentration 






Figure 4.8 Decay of Tolerance to DAMGO in the LM/MP of Guinea Pigs Treated for 7 Days 
For all concentration response curves: green line = morphine treated group, black line = placebo 
treated group. 
A)  Average DAMGO concentration response curve for 7 day – 0 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 3.266 and was significantly different from 1 (p value = 
0.0074).   
B)  Average DAMGO concentration response curve for 7 day – 1 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 1.952 and was not significantly different from 1 (p value 
= 0.0523). 
C)  Average DAMGO concentration response curve for 7 day – 2 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 1.563 and was significantly different from 1 (p value = 
0.0179). 
D)  Average DAMGO concentration response curve for 7 day – 4 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 0.964 and was not significantly different from 1 (p value 
= 0.9104). 
E)  Summary bar graph of the morphine to placebo ratios of the IC50s from the concentration 






Figure 4.9 Decay of Tolerance to DAMGO in the LM/MP of Guinea Pigs Treated for 10 Days 
For all concentration response curves: green line = morphine treated group, black line = placebo 
treated group. 
A)  Average DAMGO concentration response curve for 10 day – 0 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 2.698 and was significantly different from 1 (p value = 
0.0138).   
B)  Average DAMGO concentration response curve for 10 day – 1 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 1.693 and was significantly different from 1 (p value = 
0.0098). 
C)  Average DAMGO concentration response curve for 10 day – 2 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 1.478 and was not significantly different from 1 (p value 
= 0.3284). 
D)  Average DAMGO concentration response curve for 10 day – 4 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 0.736 and was not significantly different from 1 (p value 
= 0.0559). 
E)  Summary bar graph of the morphine to placebo ratios of the IC50s from the concentration 






Figure 4.10 Decay of Tolerance to 2-CADO in the LM/MP of Guinea Pigs Treated for 4 Days 
For all concentration response curves: green line = morphine treated group, black line = placebo 
treated group. 
A)  Average 2-CADO concentration response curve for 4 day – 0 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 2.657 and was significantly different from 1 (p value = 
0.0206).   
B)  Average 2-CADO concentration response curve for 4 day – 1 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 1.728 and was significantly different from 1 (p value = 
0.0035). 
C)  Average 2-CADO concentration response curve for 4 day – 2 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 0.888 and was not significantly different from 1 (p value 
= 0.6116). 
D)  Summary bar graph of the morphine to placebo ratios of the IC50s from the concentration 






Figure 4.11 Decay of Tolerance to 2-CADO in the LM/MP of Guinea Pigs Treated for 7 Days 
For all concentration response curves: green line = morphine treated group, black line = placebo 
treated group. 
A)  Average 2-CADO concentration response curve for 7 day – 0 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 2.976 and was significantly different from 1 (p value = 
0.0319).   
B)  Average 2-CADO concentration response curve for 7 day – 1 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 2.670 and was not significantly different from 1 (p value 
= 0.0627). 
C)  Average 2-CADO concentration response curve for 7 day – 2 day animals (n = 6).  The 
morphine to placebo ratio of the IC50 = 1.662 and was not significantly different from 1 (p value 
= 0.1885). 
D)  Average 2-CADO concentration response curve for 7 day – 4 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 0.902 and was not significantly different from 1 (p value 
= 0.7748). 
E)  Summary bar graph of the morphine to placebo ratios of the IC50s from the concentration 







Figure 4.12 Decay of Tolerance to 2-CADO in the LM/MP of Guinea Pigs Treated for 10 Days 
For all concentration response curves: green line = morphine treated group, black line = placebo 
treated group. 
A)  Average 2-CADO concentration response curve for 10 day – 0 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 2.965 and was significantly different from 1 (p value = 
0.0170).   
B)  Average 2-CADO concentration response curve for 10 day – 1 day animals (n = 4).  The 
morphine to placebo ratio of the IC50 = 2.223 and was not significantly different from 1 (p value 
= 0.2595). 
C)  Average 2-CADO concentration response curve for 10 day – 2 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 1.210 and was not significantly different from 1 (p value 
= 0.4513). 
D)  Average 2-CADO concentration response curve for 10 day – 4 day animals (n = 5).  The 
morphine to placebo ratio of the IC50 = 0.774 and was not significantly different from 1 (p value 
= 0.1709). 
E)  Summary bar graph of the morphine to placebo ratios of the IC50s from the concentration 









CHAPTER FIVE: WESTERN BLOT ANALYSIS OF FACTORS ASSOCIATED WITH 
THE DEVELOPMENT AND DECAY OF TOLERANCE TO MORPHINE IN THE 
LM/MP AND BRAINSTEM 
5.1 Abstract 
The development of tolerance to morphine is thought to be a homeostatic response in the 
expression of one or more cellular signaling proteins produced by chronic activation of the 
receptor-activated signaling pathway.  Any adaptive change should occur as tolerance to 
morphine develops and this change should reverse as tolerance decays.  Previous work has 
developed a time course over which tolerance to morphine develops and decays in guinea pigs 
subcutaneously injected with escalating doses of morphine.  Western blot analysis of LM/MP 
and brainstem homogenates from those animals was performed to assess the concentration of 
several receptors, subunits of the Na+/K+ ATPase, and two isoforms of PKC.  This analysis 
revealed that the expression of the µ receptor, adenosine A1 and A2a receptors, and the α2b 
adernergic receptor were unchanged by the development of tolerance in those tissues.  This 
indicates that the heterologous tolerance that was observed in the LM/MP in chapter 4 is not 
simply due to receptor downregulation.  The α1 and β1 subunits of the Na
+/K+ ATPase were also 
unchanged in the brainstem as tolerance to morphine developed.  Although not statistically 
significant, there was a trend for a decrease in the α3 subunit of the Na
+/K+ ATPase in the 
LM/MP, but not in the brainstem.  This difference in adaptation may be due to the mechanisms 
by which those tissues develop tolerance or simply the fact that there are more neurons present in 
the brainstem that are not expected to respond to morphine than are present in the LM/MP.  
PKCγ is not expressed by cells in the LM/MP, but it is present in the brainstem where there 
appears to be a trend for a decrease in expression as tolerance develops.  PKCε follows a similar 
147 
 
trend in the brainstem, but not in the LM/MP.  These data suggest that the mechanism(s) by 
which tolerance to morphine develops may be tissue dependent. 
5.2 Introduction 
The development of tolerance to opioids is thought to be a homeostatic adaptive response in 
one or more cellular signaling elements due to the continued presence of opioid agonist.  It has 
been suggested that for any adaptive change to account for the observed changes in 
responsiveness there are five criteria that must be fulfilled (Taylor & Fleming, 2001).  The 
second of these criteria states that the change must occur over a similar time course as the altered 
responsiveness.  This second criteria has been the focus of work in this laboratory for the past 
several years.  Results described in chapters 3 and 4 have provided a time course over which 
tolerance to morphine develops and decays to baseline as measured in the whole animal with 
paw pressure testing and ex vivo by measuring the responsiveness of the LM/MP to DAMGO 
and 2-CADO.  Tissues collected from these animals were used to examine the concentration of 
several of the proteins that are thought to serve an integral role in the development of tolerance 
to morphine. 
The µ receptor is an obvious protein of interest as it is the receptor that morphine acts on.  
Receptor down-regulation is one possible mechanism by which tolerance could develop upon 
chronic exposure to an agent.  Indeed, such a mechanism has been described for other types of 
GPCRs (i.e. β adrenergic receptors).  There are conflicting reports regarding the alteration in the 
number of µ receptors during the development of tolerance.  Some authors report no change in 
receptor abundance during tolerance (De Vries, Tjon Tien Ril, Van der Laan, Mulder & 
Schoffelmeer, 1993; Klee & Streaty, 1974) while others have observed a down-regulation 
(Bernstein & Welch, 1998; Yoburn, Billings & Duttaroy, 1993).  In contrast, other investigators 
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have reported an up-regulation (Fábián, Bozó, Szikszay, Horváth, Coscia & Szücs, 2002; 
Rothman et al., 1991).  To evaluate whether or not the tolerance observed in the animals used for 
studies described in the previous chapters is due to a change in the receptor number or some 
other mechanism, western blot analysis was carried out on homogenates of the LM/MP and the 
brainstem. 
This laboratory has used 2-CADO, an adenosine receptor agonist, as a marker of 
heterologous tolerance in the past.  Like morphine and DAMGO, it causes inhibition of 
neurogenic twitches in the LM/MP by hyperpolarizing myenteric ‘S’ neurons (Meng, Malanga, 
Kong, Taylor & Fleming, 1997).  However, unlike morphine it does not cause a change in input 
resistance, which would suggest that the mechanism by which this agent hyperpolarizes 
myenteric neurons is fundamentally different than that of morphine (Meng, Malanga, Kong, 
Taylor & Fleming, 1997).  Of the adenosine receptors, 2-CADO has the highest affinity for the 
A2a and the A1 receptors (Mathoôt, Soudijn, Breimer, Ijzerman & Danhof, 1996).  As mentioned 
previously, one potential mechanism to explain tolerance to an agonist is a down-regulation of 
the receptors for that agonist.  As such, the adenosine A1 and A2a receptors were proteins of 
interest.  Although they were not used in any of the experiments here, clonidine and xylazine, α2 
adrenergic receptor agonists, have been used in the past to demonstrate heterologous tolerance 
(Taylor, Leedham, Doak & Fleming, 1988).  Therefore α2 adrenergic receptors were also of 
interest.   
There is evidence that suggests tolerance in the LM/MP is due to a partial depolarization of 
the resting membrane potential of myenteric neurons caused by a reduction in the electrogenic 
contribution of the Na+/K+ ATPase (see chapter 1.6.6).  There is also evidence that suggests that 
there is a reduction of the expression of the Na+/K+ ATPase α3 subunit that correlates to the onset 
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of tolerance in pellet implanted animals (Li, Maguma, Thayne, Davis & Taylor, 2010).  There 
are two subunits to the pump with multiple isoforms of each subunit.  The catalytic subunit is the 
α subunit while the β subunit is responsible for trafficking and insertion in the membrane.  A 
reduction in either of these subunits could cause a reduction in the concentration and/or activity 
of the Na+/K+ ATPase.  Because the α1 and α3 subunits were examined previously in pellet 
implanted animals and the α3 subunit was shown to decrease, they were measured here following 
subcutaneous treatment (Li, Maguma, Thayne, Davis & Taylor, 2010).  The β1 subunit is most 
often paired with these two α subunits (Crambert et al., 2000), making it a protein of interest as 
well. 
PKC is another protein that was suggested to play an integral role in opioid tolerance (see 
chapter 1.6.4).  There are several isoforms of PKC, but only three were associated with morphine 
tolerance.  PKCγ is present only in neurons and is thought to mediate central nociception, while 
PKCα and PKCε are found in the periphery and thought to mediate nociception there.  Due to the 
limited amount of sample and that PKCγ and PKCε were more heavily implicated in the literature 
as playing a role in the development of tolerance to morphine, these two isoforms were chosen 
for western blot analysis as well. 
5.3 Experimental Protocol 
All of the methods used here are detailed in chapter 2.  Dunkin-Hartley guinea pigs were 
treated by subcutaneous injection with either morphine or saline on an escalating dose schedule 
for either 1, 2, 4, 7, or 10 days and then assessed for tolerance either 0, 1, 2, or 4 days after 
treatment as described in chapter 4.3.  After paw pressure testing, the animals were euthanized 
and their tissues harvested and frozen in liquid nitrogen until western blot analysis could be 
performed.  Thus, all tissues to be examined came from animals in which we had previously 
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obtained functional responses in the whole animal and in the LM/MP.  All western blots were 
done with whole tissue homogenates of either LM/MP or brainstem.  Homogenates were 
prepared by suspending the tissue in an appropriate amount of protease inhibitor buffer (see 
chapter 2.6.1) and homogenizing in a ground glass homogenizer until no visible chunks of tissue 
remained.  The homogenate was then spun in a centrifuge for 5 seconds at maximum speed 
(14000 rpms).  The supernatant was drawn off and spun again for 10 min at maximum speed at 
4°C.  The supernatant was then drawn off and aliquoted into microcentrifuge tubes.  The samples 
were then stored at -20°C until they were used for western blot analysis. 
Before each western blot, a BCA protein assay was performed to determine the amount of 
protein in each sample (see chapter 2.6.2).  Briefly, serial dilutions of a standard protein (BSA) 
were loaded into a 96 well plate with a blank and the samples and then incubated with the BCA 
dye reagent for 15 minutes at 37°C.  After this period the absorbance of each well was read at a 
wavelength of 562 nM using an Infinite M200 PRO plate reader (Tecan US, Research Triangle 
Park, NC).  After this, calculation of the standard curve and interpolation of the concentration of 
protein in the samples was performed using Graph Pad Prism 5 software. 
Following the BCA protein assay, the tissue homogenates were diluted 1:1 with working 
sample buffer (see chapter 2.7; Appendix D).  The samples were then separated by gel 
electrophoresis, transferred to PVDF membranes, and probed for the housekeeper protein, 
GAPDH, and one of the following proteins: µ receptor, A1 receptor, A2a receptor, α2b receptor, 
Na+/K+ ATPase α1, Na
+/K+ ATPase α3, Na
+/K+ ATPase β1, PKCγ, and PKCε (see Appendix E for 
antibody specifications and dilutions).  The Odyssey CLX® near-infrared imaging system (Li-
Cor Biosciences, Lincoln, NE) was used to visualize the proteins and the Image Studio 5.2 
software was used to perform densitometry. 
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5.4 Experimental Results 
The µ receptor, A1 receptor, A2a receptor, and α2b receptors remained largely unchanged at 
any time point measured in either the LM/MP or the brainstem (see figures 5.1-5.7).  These data 
indicate that the heterologous tolerance observed in these animals was not the result of receptor 
down-regulation in those tissues.  To examine the possibility that changes in the expression of 
the Na+/K+ ATPase subunits may play a role in the development of tolerance to morphine the 
expression of the α1, α3, and β1 subunits were measured in the brainstem and the α3 subunit in the 
LM/MP.  Consistent with previous studies from this laboratory (Li, Maguma, Thayne, Davis & 
Taylor, 2010), the α1 subunit did not change in response to morphine treatment at any time point 
measured in the brainstem (see figure 5.8).  Although the variability was too great to achieve 
statistical significance, there was approximately a 30% decrease in the amount of the α3 subunit 
in the LM/MP after 7 days of treatment (see figure 5.9).  This decrease in expression was not 
observed in the brainstem of those same animals (see figure 5.10).  The β1 subunit was also 
unaffected by morphine treatment of any duration in the brainstem (see figure 5.11).  Since PKCγ 
was not present in the LM/MP, the expression of this protein could not be measured.  However, 
in the brainstem the protein was present and there was a general trend for a decrease in the 
expression of this protein (see figure 5.12).  PKCε followed a similar trend in the brainstem.  In 
contrast, in the LM/MP, the expression of this protein appeared to trend toward an increase in 
expression as treatment length increases (see figures 5.13 and 5.14). 
5.5 Discussion 
One of the more common mechanisms that could account for the development of tolerance to 
an agonist is down-regulation of its receptor.  This has been described for a number of other 
GPCRs and because there were conflicting results in the literature regarding changes in the 
152 
 
number of µ receptors during the development of tolerance, we measured the receptor population 
using western blot analysis in both the LM/MP, a tissue in which we had functional data to 
indicate tolerance, and in the brainstem, a brain structure that contains circuits that mediate the 
antinociceptive effect of morphine.  The data show that not only was there no change in the µ 
receptor in those tissues obtained from tolerant animals, there was also no change in adenosine 
A1 and A2a receptors or in the α2b receptor populations.  The adenosine agonist 2-CADO has 
been used previously in this laboratory to demonstrate the development of heterologous tolerance 
(Barrett, Maguma & Taylor, 2011; Li, Maguma, Thayne, Davis & Taylor, 2010; Meng, Malanga, 
Kong, Taylor & Fleming, 1997).  Although activation of µ, A1, and α2 receptors hyperpolarize 
myenteric neurons, their mechanisms of action differ.  For example, this laboratory has 
previously shown that the hyperpolarizing effect of 2-CADO, unlike that of morphine, occurs 
without a change in input resistance, which would suggest that the mechanism by which 2-
CADO changes membrane potential does not involve activation of ion channels (Meng, 
Malanga, Kong, Taylor & Fleming, 1997).  The fact that the change in responsiveness to 
DAMGO and 2-CADO was nearly equivalent in magnitude without any change in the receptor 
populations would suggest that the cellular mechanism responsible for the change in 
responsiveness must involve some factor that has the capacity to affect the overall 
responsiveness of the cell and/or tissue to multiple stimuli rather than a change in the receptor 
populations. 
It was observed in the 1970s that the LM/MP from morphine tolerant guinea pigs were 
subsensitive to inhibitory stimuli and supersensitive to excitatory stimuli (Schulz & Goldstein, 
1973).  This observation was proposed to be due to an adaptive partial depolarization of the 
myenteric neurons that were acted upon by morphine (Fleming, 1999).  Such a depolarization 
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has since been observed in myenteric ‘S’ neurons that were activated by morphine but not those 
that were unaffected by the agonist.  Furthermore, no change in the threshold for action potential 
generation or in the magnitude of the hyperpolarizing effects of morphine and 2-CADO were 
observed (Leedham, Kong, Taylor, Johnson & Fleming, 1992; Meng, Malanga, Kong, Taylor & 
Fleming, 1997).  A decrease in the electrogenic contribution of the Na+/K+ ATPase to membrane 
potential has been previously reported by this laboratory to coincide with those changes (Kong, 
Leedham, Taylor & Fleming, 1997).  This decrease in Na+/K+ ATPase activity was reported to 
be due to a decrease in the abundance of the α3 subunit of this protein (Biser, Thayne, Fleming & 
Taylor, 2002).  Because these observations were made in pellet implanted animals, we examined 
the expression of several subunits of the Na+/K+ ATPase in homogenates of LM/MP and 
brainstem of subcutaneously injected animals.  Consistent with previous observations in the 
LM/MP, the α1 subunit did not change in abundance as tolerance developed (Li, Maguma, 
Thayne, Davis & Taylor, 2010).  Although we did not see a statistically significant change in the 
abundance of the α3 subunit, we did see an approximate 30% decrease in the expression in the 
LM/MP, which is consistent with the magnitude of the reduction observed in previous studies 
from both this laboratory and others (Gonzalez et al., 2012; Li, Maguma, Thayne, Davis & 
Taylor, 2010).  Interestingly, this decrease was not observed in the brainstem.  This could be due 
to some difference in the way that the brainstem develops tolerance when compared to the 
LM/MP.  Since the α3 subunit is specifically expressed in neurons and there is a much larger 
population of neurons in the brainstem, not all of which respond to morphine, a decrease in the 
abundance of this subunit could be masked simply because there is a comparatively larger 
proportion of neurons that are expected to not respond to morphine treatment in the brainstem.  
This analysis was performed in whole brainstem homogenates, thus a more precise examination 
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of specific brainstem nuclei (i.e. periaqueductal gray, etc.) that are involved with nociception 
may yield a result more consistent with the LM/MP data.   A decrease in Na+/K+ ATPase activity 
could also be due to changes in the number of β subunits as well as α subunits.  Because the α3 
subunit most often pairs with the β1 subunit (Crambert et al., 2000), the β1 subunit was examined 
in the brainstem.  There was no change in the level of β1 subunit in the brainstem, a result that 
suggests the development of tolerance to morphine does not induce a change in membrane 
trafficking of the Na+/K+ ATPase in the brainstem. 
PKCγ and PKCε have been reported to increase following chronic morphine treatment (see 
chapter 1.6.4).  Additionally, inhibition of either isoform of PKC prior to prolonged morphine 
treatment results in the mitigation of tolerance and administering inhibitors after treatment 
reverses the tolerance that has developed.  Consistent with previous reports in the literature, 
PKCγ was not detected in the LM/MP (Aley & Levine, 1997).  However, PKCε was detected in 
both the LM/MP and the brainstem.  Although not statistically significant, there did appear to be 
a trend for an increase in PKCε levels in the LM/MP.  There was not a significant change 
detected for several time points in the brainstem.  However, a general trend for a decrease in the 
expression of PKCγ and PKCε in the brainstem as tolerance to morphine develops was observed.  
These data are not consistent with most of the literature that reports an increase in these two 
proteins with the development of tolerance to morphine.  Similar to what was observed with the 
α3 subunit of the Na
+/K+ ATPase in the brainstem, this observation may be due to the fact that 
the homogenate was obtained from the entire brainstem as opposed to specific neuronal areas 
which were used by many of the other authors.  It may be the case that in specific areas 
associated with nociception PKC is increased with morphine treatment, but in other regions a 
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different set of adaptations is occurring that results in a decrease in PKC levels.  Despite the 
contradiction with the literature, the data indicate that PKC may be worth further investigation. 
This study examined the expression of several proteins that were thought to be involved in 
the development of tolerance.  Based on this protein analysis, we confirmed that the heterologous 
tolerance observed in the LM/MP is not due to receptor downregulation as none of the receptors 
measured changed significantly at any time point.  The α3 subunit of the Na
+/K+ ATPase trended 
towards a decrease in the LM/MP, but not the brainstem, as tolerance to morphine develops 
whereas the α1 and β1 subunits were unchanged.  PKCγ and PKCε trended towards a decrease as 
tolerance develops in the brainstem, but not in the LM/MP.  As such, the role of both, the Na+/K+ 




Figure 5.1 µ Receptor Abundance in LM/MP Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the µ receptor in the LM/MP.  It also contains the p and n values for 
each group.  The only statistically significant change was observed in the 4 day – 1 day animals, 
but it may have little biological significance. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 








Figure 5.2 µ Receptor Abundance in Brainstem Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the µ receptor in the brainstem.  It also contains the p and n values 
for each group.  No ratio was statistically significantly different from unity. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 






Figure 5.3 A1 Receptor Abundance in LM/MP Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the A1 receptor in the LM/MP.  It also contains the p and n values for 
each group.  The only statistically significant change was observed in the 4 day – 0 day animals, 
but it may have little biological significance. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 








Figure 5.4 A1 Receptor Abundance in Brainstem Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the A1 receptor in the brainstem.  It also contains the p and n values 
for each group.  The only statistically significant change was observed in the 10 day – 4 day 
animals, but it may have little biological significance. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 






Figure 5.5 A2a Receptor Abundance in LM/MP Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the A2a receptor in the LM/MP.  It also contains the p and n values 
for each group.  The only statistically significant change was observed in the 10 day – 0 day 
animals, but it may have little biological significance. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 








Figure 5.6 A2a Receptor Abundance in Brainstem Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the A2a receptor in the brainstem.  It also contains the p and n values 
for each group.  The only statistically significant changes were observed in the 1 day – 0 day and 
2 day – 0 day animals, but those changes may have little biological significance. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 






Figure 5.7 α2b Receptor Abundance in Brainstem Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the α2b receptor in the brainstem.  It also contains the p and n values 
for each group.  The only statistically significant change was observed in the 4 day – 0 day but 
that change may have little biological significance. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 







Figure 5.8 Na+/K+ ATPase α1 Subunit Abundance in Brainstem Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the Na+/K+ ATPase α1 subunit in the brainstem.  It also contains the 
p and n values for each group. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 







Figure 5.9 Na+/K+ ATPase α3 Subunit Abundance in LM/MP Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the Na+/K+ ATPase α3 subunit in the LM/MP.  It also contains the p 
and n values for each group.  Only the 4 day – 2 day animals displayed a significant decrease in 
the abundance of this protein. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 







Figure 5.10 Na+/K+ ATPase α3 Subunit Abundance in Brainstem Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the Na+/K+ ATPase α3 subunit in the brainstem.  It also contains the 
p and n values for each group.  The 2 day – 0 day and 4 day – 1 day animals displayed a 
significant decrease in the abundance of this protein. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 







Figure 5.11 Na+/K+ ATPase β1 Subunit Abundance in Brainstem Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of the Na+/K+ ATPase β1 subunit in the brainstem.  It also contains the 
p and n values for each group.  There were statistically significant increases in the abundance of 
this protein in the 4 day – 0 day and 10 day – 0 day animals. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 







Figure 5.12 PKCγ Abundance in Brainstem Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of PKCγ in the brainstem.  It also contains the p and n values for each 
group.  There were statistically significant decreases in the abundance of this protein in the 1 day 
– 0 day, 7 day – 2 day, and 7 day – 4 day animals.  There is also a general trend for a decrease 
across all time points. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 







Figure 5.13 PKCε Abundance in LM/MP Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of PKCε in the LM/MP.  It also contains the p and n values for each 
group.   
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 







Figure 5.14 PKCε Abundance in Brainstem Homogenates 
A)  This table contains the average morphine to placebo ratio of the densitometric units 
(normalized to GAPDH) of PKCε in the brainstem.  It also contains the p and n values for each 
group.  There were statistically significant decreases in the abundance of this protein in the 4 day 
– 2 day, 10 day – 0 day, 10 day – 2 day, and 10 day – 4 day animals.  There is also a general 
trend for a decrease across all time points. 
B)  This presents the average morphine to placebo ratio of densitometric units (normalized to 








CHAPTER SIX: CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Conclusions 
The development of tolerance to morphine, and opioids in general, presents a serious 
obstacle to the effective management of pain in patients who suffer from severe, chronic pain.  
Tolerance to opioids occurs as a result of prolonged and repeated exposure to an opioid agonist 
such as morphine.  It is believed that tolerance to morphine is the result of homeostatic adaptive 
changes in one or more of the cellular signaling elements involved in mediating the acute actions 
of the agonist.  However, despite nearly a century of research, the precise cellular mechanism(s) 
that is/are responsible for the development of tolerance to morphine remain elusive.  There are 
five criteria that have been proposed that must be fulfilled in order for any proposed cellular 
mechanism to be identified as accounting for an observed change in responsiveness.  “The 
proposed cellular change must: 1) be induced by experimental procedures identical to those that 
induce tolerance and/or dependence; 2) follow a similar time course as the tolerance and/or 
dependence in that tissue; 3) quantitatively account for the tolerance and/or dependence; 4) 
account for the qualitative characteristics of the tolerance and/or dependence; and 5) occur in the 
very cells upon which the opioid is acting (Taylor & Fleming, 2001)”.  There are a number of 
hypotheses that have been put forth to explain the development of tolerance to morphine (see 
chapter 1.6).  However, not all of these hypotheses have fulfilled all five criteria at the present 
time.  Work from this laboratory has focused on the decrease in the abundance of the α3 subunit 
of Na+/K+ ATPase as a possible mechanism for the development of tolerance and has generated 
data that satisfies all but the second criteria in the guinea pig LM/MP preparation (see (Taylor & 
Fleming, 2001)).  Many laboratories tend to use single time points (usually 4 or 7 days after 
treatment) for their studies and thus cannot satisfy the second criterion.  Previous work from this 
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laboratory has attempted to fulfill criterion two and has demonstrated that the expression of the 
α3 subunit of the Na
+/K+ ATPase does decrease over a similar time course as that for tolerance to 
develop and this change in protein expression reverses as tolerance fades (Li, Maguma, Thayne, 
Davis & Taylor, 2010). However, the actual time course for decay of tolerance back to baseline 
could not be accurately characterized because of the nature of the pellet implantation method of 
administration of morphine.  With pellet implantation there is uncertainty as to when all of the 
morphine has left the pellet and thus a time zero from which to evaluate the return cannot be 
defined.  Therefore, this project has focused on accurately developing a time course for the onset 
and decay of tolerance in guinea pigs treated with morphine using a parenteral method of 
administration which allows definition for the cessation of treatment in order to fulfill the second 
criterion. 
The guinea pig was chosen as a model animal to study the cellular mechanisms of tolerance 
to morphine over some of the more commonly used animals for a number of reasons.  Firstly, the 
distribution of opioid receptors in the guinea pig brain is more similar to that of humans than that 
of mice or rats (Mansour, Khachaturian, Lewis, Akil & Watson, 1988).  Guinea pigs also have a 
pharmacological response to morphine that is more similar to that of humans than that observed 
in mice and rats.  Mice and rats also display a locomotor response to morphine whereas humans 
and guinea pigs do not (Bot, Chahl, Brent & Johnston, 1992).  Furthermore, the guinea pig 
LM/MP has been employed as an ex-vivo model system to demonstrate and study tolerance to 
opioids since the 1970s (Goldstein & Schulz, 1973). 
This project had two specific aims; the first was to generate a time course for the onset and 
offset of tolerance to morphine in the guinea pig using injections as the method of 
administration.  The second hypothesis was to perform an analysis of the expression of several 
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proteins that were thought to be intimately involved in the development of tolerance to morphine 
using the tissues from which functional data had been gathered in the first aim.  Previous work in 
the laboratory had shown that various methods of inducing tolerance all produced a tolerance 
that is qualitatively and quantitatively similar (Li, Maguma, Thayne, Davis & Taylor, 2010).  
Intraperitoneal injections had not been used as a method of administration in that study so this 
method of administration was employed so as to compare the magnitude and characteristics of 
the tolerance generated with that of the other methods.  Because of the dosing issue present in 
that study (see chapter 3), we were not able to obtain any paw pressure data in the whole animal.  
The absence of an antinociceptive response was likely due to the fact that the dose of morphine 
was insufficient to provide significant analgesia.  Despite this, we were able to obtain dose-
response curves in the LM/MP for DAMGO and 2-CADO indicating that we were able to 
generate tolerance in these animals.  Unfortunately there was considerable variability in those 
data that was likely due to the variable absorption of the drug using that method of 
administration.  We were not able to achieve a statistical difference with the DAMGO IC50 
placebo to morphine ratios after 7 days of treatment, a time point at which virtually all of the 
previous studies and the literature reports the presence of tolerance to morphine. We believe that 
intraperitoneal injections resulted in variable absorption of morphine from the gut and thus 
generated higher variability in the data.  Unfortunately, this effect seems to predominate in 
animals that were treated for 7 days but not other times.  However, for the animals that did 
display tolerance, the magnitude of the IC50 shift for both DAMGO and 2-CADO were 
comparable to what was observed with subcutaneous injection and pellet implantation previously 
(Li, Maguma, Thayne, Davis & Taylor, 2010). 
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Because it was expected that the LM/MP should be supersensitive to excitatory stimuli, 
nicotine concentration response curves were also generated in these same LM/MP preparationss.  
Although supersensitivity was observed previously in pellet implanted animals (Barrett, Maguma 
& Taylor, 2011; Johnson, Westfall, Howard & Fleming, 1978), the results were highly variable 
such that a trend was not observable in this study.  The method of administration may be the 
cause of the lack of supersensitivity to nicotine.  Pellet implantation is a form of constant dosage 
in which high concentrations are immediately released and decline over time whereas injections 
are episodic.  It has been shown in rats that during the time between injections the animals 
undergo a partial withdrawal from morphine and over the period of treatment, this puts the 
animal in a state of constant stress (Houshyar, Gomez, Manalo, Bhargava & Dallman, 2003).  
There is known to be a connection between chronic activation of the HPA axis and the function 
of nicotinic receptors (Lutfy et al., 2006) and it may be that the chronic stress state induced by 
the injections suppresses the supersensitivity that was observed in pellet implanted animals.  The 
fact that we saw no supersensitivity to nicotine does not exclude the possibility that generalized 
supersensitivity may still exist in the LM/MP.  Previous work has demonstrated supersensitivity 
in the LM/MP to 5-HT and to K+ (Johnson, Westfall, Howard & Fleming, 1978). 
Based on the work in chapter 3, we determined that IP injections may not be the best method 
of administration to use for a time course study because of the greater variability in the data 
when compared to other methods of administration.  Because injections were necessary to more 
appropriately characterize the decay of tolerance to morphine, we chose to use subcutaneous 
injections to induce tolerance.  Subcutaneous injections have been shown previously to 
successfully induce tolerance that was indistinguishable from the tolerance induced by pellet 
implantation (Li, Maguma, Thayne, Davis & Taylor, 2010).  Although IP injections were not 
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optimal for studying tolerance, certain observations were made that led to changes in the 
experimental design of the work described in chapter 4.  Significant tolerance was observed after 
only 4 days of treatment. Therefore, we added groups of animals that were treated for 1 or 2 days 
in order to more accurately characterize the time course for the onset of tolerance.  No other 
studies have evaluated the characteristics of the response after 2 days of treatment.  Because we 
did not see a significant difference in the return of the DAMGO and 2-CADO IC50 ratios to 
normal 2 days after treatment in animals that were treated for 7 or 10 days, we added groups of 
animals that were assessed for tolerance 1 day after both 7 and 10 days of treatment.  The dosing 
issue present in chapter 3 was also corrected, allowing successful assessment of development of 
tolerance with paw pressure testing. 
With the modified design, the experiments performed that are presented in chapter 4 were 
able to provide a more complete time course for the onset and offset of tolerance to morphine.  
Based on paw pressure AUCs and the morphine to placebo ratios of DAMGO and 2-CADO it 
appears that significant tolerance began to develop within 2 days of treatment.  After 4 days of 
treatment, the magnitude of tolerance had reached a peak that was indistinguishable from the 
level of tolerance obtained from animals treated for 7 or 10 days.  Despite this apparent peak in 
tolerance by 4 days that remained constant throughout the treatment period, the animals treated 
for 7 or 10 days were still tolerant, or close to it, 2 days after the cessation of treatment, whereas 
animals treated for only 4 days returned to baseline levels of sensitivity at this time point.  This 
suggests that more extensive changes occurred in the animals treated for longer periods of time 
than in the animals treated for shorter periods of time.  These data are consistent with our 
hypothesis that the magnitude of the changes responsible for the development of tolerance 
depends on the length of treatment.  Tissues from these animals were collected so that a western 
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blot analysis of several different cellular proteins could be performed on the same tissues in 
which the functional data were obtained. 
Because the development of tolerance to morphine is thought to be due to adaptive changes 
in protein expression or function, we measured the expression of several proteins that have been 
previously implicated as playing a role in the development of the phenomenon.  Receptor 
downregulation is a common mechanism by which tolerance or reduced responsiveness could 
develop in a variety of GPCRs.  There also have been some conflicting reports as to the direction 
and number of receptors present during the development of a tolerant state.  Therefore, the µ 
receptor was considered to be a protein of interest.  Experiments performed in chapter 5 
demonstrated that in both LM/MP and brainstem homogenates the expression of the µ receptor 
does not change at any time point that was measured.  In fact, none of the receptors examined 
changed significantly as a result morphine treatment.  These data suggest that receptor down-
regulation is unlikely to be the mechanism driving the appearance of the heterologous tolerance 
observed in experiments in animals and ex vivo tissue described in chapter 4. 
There are data that satisfy all but the second criteria in order to establish that a potential 
mechanism that could explain the heterologous tolerance observed in the LM/MP is a decrease in 
the electrogenic contribution of the Na+/K+ ATPase to resting membrane potential (Taylor & 
Fleming, 2001).  The Na+/K+ ATPase is composed of catalytic α subunits and β subunits 
responsible for membrane trafficking and insertion. A possible explanation for the observed 
decrease in the electrogenic contribution of the Na+/K+ ATPase would be a decrease in the 
abundance of either the α or the β subunits of the Na+/K+ ATPase, leading to a reduction in the 
total number of functional Na+/K+ ATPase units.  A previous study from this laboratory had 
demonstrated that chronic morphine treatment results in a decrease in the level of the α3 subunit 
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in the guinea pig LM/MP using dot blots analysis (Li, Maguma, Thayne, Davis & Taylor, 2010) 
and another laboratory has observed a decrease of a similar magnitude in the plasma membrane 
fraction of the rat forebrain in an α subunit they believe to be the α3 subunit using mass 
spectroscopy (Prokai, Zharikova & Stevens, 2005).  Until now, the Na+/K+ ATPase subunits 
have only been examined at single time points or with pellet implanted animals which prevented 
an accurate assessment of the decay of tolerance back to baseline.  We examined the α1, α3, and 
β1 subunits in the brainstem and the α3 subunit in the LM/MP.  We observed no change in any 
subunit in the brainstem but there did appear to be a trend for a decrease in the abundance of the 
α3 subunit with morphine treatment that returned to baseline by 4 days after the treatment ended.  
Although statistical significance could not be achieved, the magnitude of the decrease was 
similar to that previously reported in the literature (Li, Maguma, Thayne, Davis & Taylor, 2010; 
Prokai, Zharikova & Stevens, 2005).  The lack of a change in the expression of the α3 subunit in 
the brainstem was not expected and may be due to the fact that there are a larger proportion of 
neurons in that brain area that would not be expected to participate in the response to morphine 
thereby masking a decrease in expression.  It may also reflect a difference in the way that the 
brainstem develops tolerance compared to the LM/MP.  Further investigation will be necessary 
to explain this discrepancy.  
The final set of proteins examined were the γ and ε isoforms of PKC.  Expression of these 
two isoforms has been reported to increase in tolerant animals.  The results obtained in the 
present study indicated that PKCγ is not present in the LM/MP, which is consistent with previous 
reports in the literature (Aley & Levine, 1997).  Therefore, PKCε was examined in the LM/MP 
and, while present in the tissue, was not observed to significantly change at any time point 
measured.  However, a trend for an increase in expression of that protein was observed as 
191 
 
treatment length increased.  Though not statistically significant, there appeared to be trend for a 
decrease in the abundance of both isoforms of PKC in the brainstem.  This observation is not 
consistent with most of the reported literature.  The cause of this discrepancy could be the fact 
that whole brainstem homogenates were employed instead of specific nuclei within the brainstem 
that may be more integral to the nociception pathway.  It may be that PKC does increase in 
specific nuclei that are involved with nociception, but neurons in other brain nuclei that are not 
involved in nociception respond to chronic treatment with morphine differently and decrease.  
Because the trend is not statistically significant and an opposing trend was observed in the 
LM/MP, the trend may not reflect anything beyond biological variability.  Another possibility 
that could explain the difference between the brainstem and LM/MP is that these two tissues 
develop tolerance by different mechanisms, resulting in a decrease in the α3 subunit Na
+/K+ 
ATPase in the LM/MP but not in the brainstem, and no change in PKC levels in the LM/MP but 
a decrease in the brainstem.  However, further experiments would be necessary to confirm this. 
In summary, this project has provided a time course for the onset and offset of tolerance to 
chronic morphine treatment following escalating doses of morphine delivered by either 
intraperitoneal or subcutaneous injections in the guinea pig.  A significant level of tolerance 
begins to develop after only 2 days of treatment.  By 4 days of treatment, heterologous tolerance 
is evident in the LM/MP based on the IC50 ratios of DAMGO and 2-CADO.  Although there is 
no significant difference in the magnitude of tolerance that develops in response to chronic 
morphine between the 4, 7, and 10 day treatments, it does appear to take longer for animals 
treated for 7 and 10 to return to baseline (4 days) than for animals treated for 4 days (2 days).  
These data may indicate that more extensive adaptations occurred in the animals treated for 
longer periods of time.  The tolerance observed in those animals is not due to changes in the µ 
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receptor, or any other receptor measured, in either the LM/MP or the brainstem as determined by 
western blot analysis.  Although nothing significant was observed, there was a trend for a 
decrease in the level of the α3 subunit Na
+/K+ ATPase in the LM/MP, but not the brainstem.  
There was also a trend for a decrease in the level of both the γ and ε isoforms of PKC in the 
brainstem but not in the LM/MP.  The time course generated here could provide a useful tool for 
examining the expression of other proteins that have been implicated in the development of 
opioid tolerance. 
6.2 Future Directions 
There are several types of experiments that could be performed to further the goal set forth 
by this project.  One interesting experiment would be to change the method of administration of 
morphine to one that combines the lower animal stress of pellet implantations with the ability to 
stop dosing at will.  There are programmable osmotic mini pumps available now from Alzet that 
would allow dose increases similar to what was used in our subcutaneous injection schedule by 
increasing the rate of infusion after a period of time.  This method of administrations also allows 
for continuous infusion of drug, similar to pellet implantation, which prevents the partial 
withdrawal between doses that the animal experiences with injections but still allows for the 
dosing to be stopped at a defined point in time.  In using this method of administration, it may be 
possible to show supersensitivity of the LM/MP to nicotine which may have been masked by the 
stress the injections put on the animals.  Another possibility would be to generate concentration 
response curves for 5-HT or K+ instead of nicotine, agents that the LM/MP has previously been 
shown to develop supersensitivity in morphine tolerant animals (Johnson, Westfall, Howard & 
Fleming, 1978).  The ability to demonstrate supersenitivity to excitatory stimuli and 
subsensitivity to inhibitory stimuli over the time course generated here would provide greater 
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evidence that tolerance is the result of a generalized change in membrane potential.  Such a 
mechanism would explain why tolerance is observed to the inhibitory effects of several different 
agonists (in this project; morphine, DAMGO, and 2-CADO) without a change in the receptor 
populations of any of these agonists. 
Another experiment that would be interesting to perform would be activity assays for the 
Na+/K+ ATPase and PKC.  Because the protein levels did not change in the way they were 
expected to, it would be interesting to see if the activity of these proteins changed in the 
appropriate direction.  Additionally analysis of the mRNA of these proteins using quantitative 
RT-PCR would provide insight into the nature of the change in protein expression.  These studies 
would allow the determination of whether or not the observed changes in the protein levels were 
due to changes in synthesis or not.  Another experiment of interest would be a more thorough 
examination of the brainstem.  Instead of looking at homogenates of whole brainstem, certain 
portions of the brainstem that play a role in nociceptive signaling, such as the periaqueductal 
gray, could be excised and examined individually.  Such studies may correct the issues with the 
brainstem analysis that were performed in these studies.  Although some mechanistic work has 
been done with Na+/K+ ATPase and PKC (see chapter 1.6.4 and 1.6.6), it would be interesting to 
do more of it with the time course generated here.  For example, one could inhibit the α3 subunit 
of the Na+/K+ ATPase from a placebo animal using a low (nM) dose of ouabain in the organ bath 
set up used for the ex-vivo experiments in chapters 3 and 4.  If the α3 subunit of the Na
+/K+ 
ATPase was decreased in either expression or activity during the development of morphine 
tolerance, artificially inhibiting the activity of the pump in a placebo animal and then 
constructing concentration response curves for DAMGO and 2-CADO in the LM/MP should 
generate an alteration in responsiveness that is similar to that observed in morphine tolerant 
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animals.  Conversely, overexpression of the α3 subunit Na
+/K+ ATPase in morphine tolerant 
animals should mitigate the development of tolerance to some degree.  Similar types of 
experiments could be done with the α, γ, and ε isoforms of PKC.  Some of these types of 
experiments have been performed (see chapter 1.6.4) but most of that work has not been done in 
a guinea pig using the LM/MP as a model system. 
Of the five criteria that were proposed (Taylor & Fleming, 2001) that must be fulfilled in 
order to establish a proposed mechanism as truly being able to account for the observed changes 
in responsiveness, the second criterion regarding the time course is generally lacking in most of 
the current literature.  Most authors tend to focus on single time points, usually 4 or 7 days of 
treatment, where the animal is known to be tolerant.  The work described in these studies has 
provided a time course which can now be used to verify several of the other mechanisms 
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APPENDIX B:  KREBS – HENSELEIT BUFFER 







Sodium Chloride 58.44 66.00 1.13 M 
Potassium Chloride 74.56 3.54 47 mM 
Calcium Chloride 110.99 2.80 25 mM 
Magnesium Sulfate 246.5 2.94 12 mM 
Dextrose 180.16 10.00 56 mM 
Final Volume (bring to with distilled water)  1 L  
Store at 4°C 







Potassium Phosphate Monobasic 136.09 1.61 11.8 mM 
Sodium Bicarbonate 84.10 21.00 250 mM 
Final Volume (bring to with distilled water)  1 L  
Store at 4°C 
To make 1 L of the working solution: (1X solution) MAKE FRESH DAILY 
1) Add 100 mL of the 10X Stock “A”  
2) Add some distilled water 
3) Add 100 mL of the 10X Stock “B” 
4) Bring volume to 1 L with distilled water 






APPENDIX C:  PROTEASE INHIBITOR BUFFER 
Components 
Chemical Constitution Concentration Notes 
Phenylmethyl Sulfonyl 
Fluoride(PMSF) 





recommends. It will 
go into solution by 
heating at 55°C for 
5 min. Make fresh 
daily. 
Bacitracin 
50 mg into 500 µL of 
distilled water then add 
500 µL of distilled 
water 
50 mg/mL 
May require heating 
at 55°C for 10-15 
min to go into 
solution. Store at < 
0°C. 
4-Aminobenzamindine 
50.4 mg into 1 mL of 
distilled water 
242 mM Store at < 0°C. 
Ethylenediaminetetraacet
ic acid (EDTA) 
46.53 g into 500 mL of 
distilled water 
250 mM 
















PMSF 0.5 mL 0.25 mL 0.125 mL 4.08 mM 
Bacitracin 500 µL 250 µL 125 µL 1 mg/mL 
4-Aminobenzamidine 100 µL 50 µL 25 µL 1 mM 
Sucrose 2.14 g 1.07 g 0.535 g 0.25 mM 
EDTA 1 mL 0.5 mL 0.25 mL 10 mM 
Final Volume (bring to 
with distilled water) 







APPENDIX D:  WESTERN BLOT BUFFERS 
10X Running Buffer 
Chemical Amount Final Concentration 
Tris-Base 30.28 g 0.25 M 
Glycine 150.14 g 2 M 
Sodium Dodecyl Sulfate (SDS) 10.00 g 1% 
pH to 8.6 and bring volume to 1 L with distilled water 
Dilute 1:10 for working solution.  
Store at room temperature. 
 
10X Phosphate Buffered Saline (PBS) 
Chemical Amount Final Concentration 
Sodium Chloride 
80.00 g 1.4 M 
Potassium Chloride 
2.00 g 2.6 mM 
Sodium Phosphate Dibasic 
14.40 g 101.4 mM 
Potassium Phosphate 
Monobasic 
2.40 g 17.6 mM 
pH to 7.4 and bring volume to 1 L with distilled water 
Dilute 1:10 for working solution. 
Store at room temperature. 
 
1X Phosphate Buffered Saline – 0.1% Tween 20 (PBS-T) 
1) 100 mL 10X PBS 
2) 1.0 mL Tween-20 




1X PBS-T with 0.02% SDS 
1) 500 mL of 1X PBS-T 
2) 0.1 g of Sodium Dodecyl Sulfate (SDS). Store at room temperature. 
 







2.364 g into 30 mL of 
distilled water 
0.5 M 
pH to 6.8 
Store at room 
temperature 
10% Sodium Dodecyl 
Sulfate (SDS) 
1 g into 10 mL of distilled 
water 
10% 
Store at room 
temperature 
Bromophenol Blue 
0.000157 mg into 10 mL 
of distilled water 
15.7 µM 
Store at room 
temperature 
 
To make the working solution: 
Chemical Amount 
0.5 M Tris-HCl pH 6.8 1.25 mL 
10% SDS 2.00 mL 
Glycerin 1 g 
2-Mercaptoethanol (β-ME) 0.5 mL 
Bromophenol Blue 200 µL 
Bring to 10 mL with distilled water.  





























Mouse 1:30000 1:30000 36 Millipore MAB374 
β3 Tubulin 
Rabbit 1:2000 N/A 50 Abcam 18207 
β3 Tubulin 
Mouse 1:2000 N/A 50 Abcam 118627 
µ Receptor 
Rabbit 1:2000 1:1000 45 Chemicon AB5511 
A1 Receptor 
Rabbit 1:1000 1:1000 36 Abcam 82477 
A2a Receptor 
Mouse 1:100 1:100 45 Abcam ab79714 
α2b Receptor 
Rabbit 1:5000 1:5000 50 Abcam ab151727 
α1 subunit of the 
Na+/K+ ATPase 
Mouse 1:500 1:1000 110 Abcam ab7671 
α3 subunit of the 
Na+/K+ ATPase 
Mouse 1:500 1:1000 110 ThermoFisher XVIF9-G10 
β1 subunit of the 
Na+/K+ ATPase 
Mouse 1:1000 1:1000 48-55 Millipore 05-382 
Protein Kinase Cγ 
Rabbit N/A 1:1000 78 Abcam 71558 
Protein Kinase Cε 
Rabbit 1:1000 1:1000 82 Cell Signaling 4376 
All primary antibodies were diluted in Odyssey Blocking Buffer with 0.1% Tween 20 and 





Host Conjugated Dye Dilution Antibody Source Catalogue # 
Goat anti-rabbit IRDye 680 LT 1:30000 Li-Cor Biosciences 926-68021 
Goat anti-mouse IRDye 800 CW 1:30000 Li-Cor Biosciences 926-32210 
Goat anti-rabbit IRDye 800 CW 1:30000 Li-Cor Biosciences 926-32211 
Goat anti-mouse IRDye 680 LT 1:30000 Li-Cor Biosciences 926-68020 
All secondary antibodies were diluted in PBS-T with 0.02% SDS and stored at 4°C until 
use. 
Protect secondary antibody solutions from light. 
  
 
 
 
 
 
